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Mg2+ magnesium ion
ms milliseconds
Na+ sodium ion
PKA protein kinase A
PCCD progressive cardiac conduction defect
QT
c
 QT interval corrected for heart rate
RWS Romano-Ward syndrome
RYR1 ryanodine receptor, type 2
RYR1 gene for ryanodine receptor, type 1
RYR2 ryanodine receptor, type 2
RYR2 gene for ryanodine receptor, type 2
RYR3 ryanodine receptor, type 3
RYR3 gene for ryanodine receptor, type 3
SCN5A cardiac voltage-gated sodium channel
SCN5A gene for sodium channel, voltage-
gated, type V, alpha
SERCA sarco/endoplasmic reticulum calcium 
ATPase
SR sarcoplasmic reticulum
WPW Wolf-Parkinson-White syndrome
In addition, standard one letter abbreviations for 
nucleotides and amino acids are used.
AF atrial fibrillation
AnkB the gene for ankyrin B
AP action potential
ARVD arrhythmogenic right ventricular 
dysplasia
ATP adenosine triphosphate
bpm beats per minute
BS Brugada syndrome
Ca2+ calcium ion
CACNA1C cardiac L-type calcium channel
cAMP cyclic adenosine monophosphate
CASQ2 calsequestrin, type 2
CASQ2 the gene for calsequestrin, type 2
CCD central core disease
cM centiMorgan
CPVT catecholaminergic polymorphic 
ventricular tachycardia
DCM dilated cardiomyopathy
DHPLC denaturing high-performance liquid 
chromatography
ECG electrocardiogram
FKBP12.6 FK506 binding protein 1B, 12.6 kDa
FKBP1B gene for FKBP12.6
HCM hypetrophic cerdiomyopathy
HERG cardiac voltage-gated potassium 
channel
HERG human ether a-go-go related gene
I
Ca
 cardiac calcium current
I
Ks
 slow component of the delayed 
rectifier current
I
Kr
 rapid component of the delayed 
rectifier current
I
Na
 cardiac sodium current
JLNS Jervell and Lange-Nielsen syndrome
K+ potassium ion
KCNE1 gene for potassium voltage-gated 
channel, Isk-related family, member 1
KCNE2 gene for potassium voltage-gated 
channel, Isk-related family, member 2
KCNQ1 cardiac voltage-gated potassium 
channel
KCNQ1 gene for potassium voltage-gated 
channel, KQT-like subfamily, 
member 1
LQTS long QT syndrome
MH malignant hyperthermia
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morphological or histological abnormalities 
of the cardiac muscle are observed in affected 
individuals. Both autosomal dominant and 
recessive inheritance have been described, 
with the dominant form more prevalent, yet 
very rare. At the beginning of this study, 
the gene underlying this life-threatening 
disorder had been mapped to chromosome 
1q42-43, but the molecular pathogenesis of 
the disease was completely unknown.
The present study aimed at dissecting 
the genetic background of LQTS and 
CPVT. The HERG gene known to underlie 
LQTS was screened for mutations by direct 
sequencing. The chromosomal location of 
CPVT locus was further delineated with 
a dense panel of microsatellite markers. 
Mutation screening was performed for 
several positional and functional candidate 
genes. 
As one of the principal results of this 
study, the gene coding for ryanodine 
receptor type 2 (RYR2) was shown to 
underlie CPVT. Six mutations: V2306I, 
P2328S, Q4201R, V4653F, P4902L, 
and R4959Q were detected in Finnish 
families and were shown to co-segregate 
with the disease phenotype. Functional 
consequences of the mutations P2328S, 
Q4201R, and V4653F were studied in 
single-channel experiments. The mutated 
Inherited arrhythmias as disorders are 
rare, but have major clinical importance. 
The best known of these diseases is long 
QT syndrome (LQTS). It manifests with 
prolonged QT interval in electrocardiogram, 
ventricular tachycardias, syncope (sudden 
loss of consciousness), and sudden death. 
The trait can be inherited as autosomal 
dominant (Romano-Ward syndrome, RWS) 
or autosomal recessive (Jervell and Lange-
Nielsen syndrome, JLNS). Of these, RWS 
is more common, having an approximate 
prevalence of 1:5 000. In the extremely rare 
JLNS, the cardiac manifestations are more 
severe and are accompanied by congenital 
deafness. Seven genes have been identified 
as underlying the LQTS phenotypes. Six of 
these, including KCNQ1, HERG, SCN5A, 
KCNE1, KCNE2, and KCNJ2, encode 
cardiac ion channels, whereas the gene 
product of AnkB is a membrane-targeting 
protein. LQTS displays considerable 
genetic and phenotypic heterogeneity as 
well as variable penetrance.
Catecholaminergic polymorphic 
ventricular tachycardia (CPVT) has its 
onset in adolescence and is characterized 
by ventricular tachyarrhythmias induced by 
physical or emotional stress. It is inherited 
with almost complete penetrance and 
if left untreated, has high mortality. No 
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RYR2 channels showed reduced binding 
affinity to the regulatory protein FKBP12.6 
and when phosphorylated, displayed 
significantly increased activities consistent 
with a gain-of-function abnormality. 
In addition, the mutant channels were 
resistant to inhibition by physiological 
concentrations of magnesium. 
Furthermore, genetic analysis of the 
HERG gene disclosed a total of nine 
mutations (453delC, R176W, P451L, 
1631delAG, L552S, Y569H, G584S, 
G601S, and T613M) in LQTS patients. 
One of these mutations, L552S, was 
detected in several families and represented 
a Finnish founder mutation (HERG-
Fin). In functional studies, HERG-Fin 
displayed a marked increase in its rate 
of deactivation, which is suggested to 
result in decreased channel activity at 
the end of the repolarization phase. The 
first common amino acid polymorphism 
(K897T) of this gene was also described in 
this study and its effect on the QT interval 
examined in a cohort of LQTS mutation 
carriers. A suggestive genotype-phenotype 
relationship was demonstrated.
The results of this study can be applied 
to the molecular diagnosis of affected 
family members. Because the Finnish 
founder mutation HERG-Fin accounts for 
approximately 5% of all Finnish LQTS 
cases, it is presently used in routine 
screening of all LQTS probands. The 
identification of the gene underlying 
CPVT has enabled early presymptomatic 
diagnosis in the families. Furthermore, 
the pathological mechanism resulting in 
this devastating disease is revealed, with 
direct implications for pharmacological 
interventions suggested.
INTRODUCTION
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Sudden cardiac death constitutes one of 
the leading causes of mortality in western 
countries. A minor but clinically significant 
portion of these deaths is the consequence 
of an inherited predisposition to cardiac 
arrhythmias. During the last decade, the 
genetic basis of these arrhythmic diseases 
has been studied intensively. The first gene 
to be localized in the genome was the one 
that underlies type 1 long QT syndrome 
(Keating et al. 1991). The first actual 
disease-causing gene identified was the 
HERG gene, whose mutations result in type 
2 long QT syndrome (Curran et al. 1995). 
To date, more than ten genes and hundreds 
of mutations underlying these fatal diseases 
have been characterized (Vincent 1998; 
Chiang and Roden 2000). 
As the knowledge of the genetic factors 
underlying arrhythmic diseases constantly 
increases, it is becoming evident that most, 
if not all, proteins taking part in cardiac 
action potential, excitation-contraction 
coupling, and formation of the myocardial 
sarcomere can harbor defects due to 
mutations in their corresponding genes. 
Identification of these genes and their 
mutations has enabled the biochemical and 
electrophysiological investigation of these 
key components of myocardial function. In 
turn, important functional aspects effective 
in the normal and diseased state of the cell 
have been revealed. Thus, disease-causing 
mutations provide us not only with new 
disease mechanisms, but also with new 
insights into cell biology.
Most of the arrhythmic diseases known 
thus far are monogenic and inherited as 
autosomal dominant traits. This picture is 
complicated by findings that one disorder 
can be due to mutations in several distinct 
genes (locus heterogeneity), and mutations 
in a single gene can lead to a variety of 
clinical phenotypes (allelic heterogeneity). 
Considerable phenotypic and genetic 
heterogeneity suggests the presence of 
modifying genes and challenges the 
traditional clinical diagnosis.
This study aimed at investigating 
the genetic background of two inherited 
arrhythmic diseases, the catecholaminergic 
polymorphic ventricular tachycardia and 
the long QT syndrome. The study led 
to identification of the gene underlying 
catecholaminergic polymorphic ventricular 
tachycardia. Several previously unknown 
mutations, including a Finnish founder 
mutation resulting in long QT syndrome 
were characterized. Functional studies on 
these genetic alterations elucidated the 
pathogenic mechanisms underlying the 
clinical phenotypes. 
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1 ELECTRICAL AND CONTRACTILE 
FUNCTIONS OF THE HEART CELL
1.1 CARDIAC ACTION POTENTIAL
A pulse of electrical excitation in a group of 
specialized pacemaker cells initiates each 
heartbeat (Marban 2002). This electrical 
impulse subsequently spreads throughout 
the heart and is known as the action 
potential (AP). The AP of ventricular cells 
is characterized by a prolonged plateau 
phase. This long plateau is important in 
two ways: calcium ions (Ca2+) that are 
necessary to initiate contraction enter the 
cell, and sodium channels are held in the 
inactive state until the depolarizing wave 
has spread to the whole electrically coupled 
myocardium (Gargus 2003). 
The plasma membrane of a resting 
cardiac myocyte is highly permeable to 
K+ and impermeable to Na+ (Roden et al. 
2002). Because resting potential of the 
plasma membrane is formed by open K+ 
channels, it is approximately –70 mV, 
close to the Nernst potential of potassium 
(Ackerman and Clapham 1997). Because 
a propagating impulse from the sinus 
node changes the potential, Na+ channels 
Figure 1. Ventricular action 
potential (top), the underlying ionic 
currents and the genes encoding the 
corresponding channels. Currents 
are depicted as function of time, 
depolarizing currents below the 
base line and repolarizing currents 
above the base line. I
Na
, cardiac 
sodium current; I
Ca,L
, cardiac L-
type calcium current; I
Na/Ca
, sodium/
calcium exhanger; I
K1
, pacemaker 
current; I
To1
 and I
To2
, transient 
outward currents; I
Kr
, rapid 
component of the delayed rectifier 
current; I
Ks
, slow component of the 
delayed rectifier current; I
Kp
, time-
independent background current. 
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alter their conformation and thus open. 
This results in rapid influx of Na+ ions and 
depolarization of the membrane (Figure 1, 
phase 0). Balance of an inward, depolarizing 
Ca2+ current and an outward, repolarizing 
K+ current maintains the long plateau phase 
(phase 1-2). The outward potassium current 
produced by delayed rectifier K+ channels 
and inactivation of Ca2+ channels (phase 
3) complete the repolarization. The final 
repolarization (phase 4) is due to the inward 
rectifier K+ channels’ producing an outward 
K+ current (see Ackerman and Clapham 
1997 and Roden et al. 2002 for review). 
1.2 POTASSIUM AND CALCIUM 
CURRENTS OF THE HEART
All voltage-gated channels share several 
fundamental functional modules (Terlau 
and Stuhmer 1998; Roden et al. 2002). 
These include a voltage sensor sensing 
the changes in membrane potential, an 
activation gate opening in response to 
the voltage sensor, and a selectivity filter 
favoring permeation of a specific ion. 
In potassium channels transmembrane 
segment S4 acts as the voltage sensor (Bao 
et al. 1999), whereas the S5 segment takes 
part in the gating process (Shieh et al. 1997) 
(Figure 2). 
The action potential is the result of the 
coordinated function of numerous voltage-
gated ion channels and the ionic currents 
they produce (Marban 2002). Some 
important ionic currents of ventricular AP 
are depicted in Figure 1. Here, only the 
major potassium and calcium currents and 
the respective ion channels are reviewed. 
Delayed rectifier K+ currents activate 
with some delay following the initial 
depolarization. The HERG (human ether a-
go-go related) gene encodes the α subunit 
Figure 2. Schematic representation of the predicted transmembrane topology of voltage-gated K+, Na+, and 
Ca2+ channels. Arrows indicate the ion-permeating pore regions. The potassium channel is formed by four 
identical α-subunits, each comprising six transmembrane domains. In sodium and calcium channels, the 
same overall structure consists of four repeats (I-IV) of six transmembrane domains. 
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of the potassium channel underlying I
Kr
, the 
rapid component of the delayed rectifier 
potassium current (Sanguinetti et al. 1995). 
The HERG gene is the human homolog 
of the Drosophila eag-gene, identified by 
the leg-shaking phenotype of the fly. The 
mature channel is a tetramer formed by four 
HERG subunits and possibly modulated by 
the auxiliary β subunit, which is encoded by 
the KCNE2 gene (Abbott et al. 1999). Each 
α subunit comprises six transmembrane 
regions and an ion-permeating pore domain 
(Warmke and Ganetzky 1994; Roden and 
George 1997) (Figure 2). The main function 
of the HERG channel is in the beginning of 
the repolarization phase, when it produces a 
large outward current that further promotes 
rapid repolarization. The unique features 
of this channel are fast inactivation and 
slow deactivation (Sanguinetti et al. 1995). 
Many drugs block the HERG channel 
(Vandenberg et al. 2001).
The KCNQ1 gene encodes the slow 
component (I
Ks
) of the delayed rectifier. 
The KCNQ1 channel is a tetramer, 
which, in addition to four α subunits, 
contains auxiliary β subunits (Sanguinetti 
et al. 1996b). The KCNE1 gene codes 
for this auxiliary β subunit (Murai et al. 
1989). Slow activation and deactivation 
characterize I
Ks
, which functions at the end 
of the repolarization phase.
The L-type (long-lasting) and T-type 
(transient, tiny or high threshold) are the 
major cardiac Ca2+ currents (I
Ca
). As 
T-type channels are mostly present in 
specialized structures of the heart, such 
as sinus and atrioventricular nodes and 
the conduction system, and as they do not 
contribute to ventricular AP, I
Ca
 usually 
refers to the L-type current.
The L-type Ca2+ current has two 
important functions: it is a major contributor 
in the inward current sustaining the long 
cardiac action potential and triggers the 
Ca2+ release needed for muscle contraction. 
The calcium is released from the 
sarcoplasmic reticulum (SR), a specialized 
type of endoplasmic reticulum (Roden et al. 
2002). L-type calcium channels are located 
on the plasma membrane invaginations 
(T-tubules). Although I
Ca
 is activated 
by membrane depolarization, calcium-
dependent inactivation at the cytoplasmic 
side limits the amount of Ca2+ entering the 
cell during the action potential (Peterson et 
al. 1999). This important feedback function 
is mediated by calmodulin, the ubiquitous 
Ca2+ sensor of cells. 
A single large α subunit (Schultz et al. 
1993), together with an auxiliary β subunit 
(Chien et al. 1995), forms the cardiac L-
type Ca2+ channel which is also called the 
dihydropyridine receptor. The CACNA1C 
gene encodes the alpha subunit (Mikami 
et al. 1989) consisting of four repeats of 
six transmembrane domains (Terlau and 
Stuhmer 1998) (Figure 2).
REVIEW OF THE LITERATURE
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1.3 EXCITATION-CONTRACTION 
COUPLING–FROM PLASMA 
MEMBRANE TO CONTRACTION 
APPARATUS
Depolarization of the plasma membrane of 
cardiac muscle cells initiates the sequence 
of electrical and biological functions 
leading to the contraction of the cardiac 
myocyte and the beating of the heart. The 
L-type calcium channels located in the 
sarcolemmal SR junctions (Figure 3) allow 
the entry of a small quantity of Ca2+ ions 
to the cell (Bers 2002). As the cytoplasmic 
calcium concentration rises, Ca2+ binds to 
the cardiac ryanodine receptor (RYR2) 
channels located on the SR and activates 
the channels. The mechanism underlying 
this activation and the termination of 
Ca2+ release from the SR has been termed 
calcium-induced calcium release (Figure 
3).
SR is an important reservoir of Ca2+ ions. 
Activated RYR2 channels release a massive 
Ca2+ spark from the SR (Wier and Balke 
1999), and the elevated Ca2+ concentration 
allows troponin C to bind Ca2+. This leads 
to conformational changes in troponin C 
protein and thereby releases the inhibition 
between actin and myosin, which results in 
contraction of the myocyte. All the proteins 
comprising this signal transduction 
apparatus are in the vicinity of each other. 
This allows the calcium concentration to 
rise locally without the disturbance of other 
signaling functions in the cell. 
Ca2+ ions must be removed from the 
Figure 3. Calcium transport in 
ventricular myocytes. RYR2, 
ryanodine receptor type 2; CASQ2, 
cardiac calsequestrin; PLB, 
phospholamban; SERCA2, cardiac 
SR calcium ATPase; PMCA, 
plasma membrane calcium ATPase; 
NCX, Na+/Ca2+ exchanger.
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cytoplasm in order to lower the calcium 
concentration and thereby allow relaxation. 
Rapid reuptake of calcium back into the SR 
is achieved by a large number of cardiac 
SR calcium ATPase pumps which are 
negatively regulated by phospholamban 
(Frey et al. 2000; Stokes and Wagenknecht 
2000). A smaller amount of Ca2+ is also 
extruded from the cell by plasma membrane 
calcium ATPase and by Na+/Ca2+ exchanger. 
This extrusion is necessary to maintain the 
calcium balance of the cell, since some of 
the Ca2+ present in the cytoplasm initially 
entered through the L-type channels. 
Together, these two systems remove 98% 
of the Ca2+, whereas the remaining 2% is 
removed by sarcolemmal Ca2+-ATPase and 
mitochondrial Ca2+ uniporter (Bers 2002).
1.4 CARDIAC CA2+ SIGNALING PROTEINS 
INVOLVED IN CALCIUM-INDUCED 
CALCIUM RELEASE
Numerous proteins contribute to the 
delicately regulated process of calcium-
induced calcium release. Here, only those 
proteins relevant for this work are discussed 
in detail. 
Ryanodine receptor, type 2 (RYR2) 
is a calcium-release channel expressed 
in the heart and brain (Otsu et al. 1990; 
McPherson and Campbell 1993). Four 565 
kDa subunits form the functional channel 
(Tunwell et al. 1996; Marx et al. 2000). 
The N-terminal part corresponding to 
approximately four-fifths of the channel 
subunit is located in the cytoplasm, while 
the remaining one-fifth (1 000 amino 
acids) form the transmembrane domains 
(Figure 4). The number of transmembrane 
segments is disputed, estimates ranging 
from 4 to 12 (Otsu et al. 1990; Tunwell et 
al. 1996; Stokes and Wagenknecht 2000). 
Recent experiments on the skeletal muscle 
homolog RYR1 suggest the presence of 
eight transmembrane domains (Du et al. 
2002). The large cytoplasmic “foot” domain 
of the channel functions as a scaffold for a 
number of regulatory proteins (Stokes and 
Wagenknecht 2000).
The functional channel is a 
macromolecular complex of four RYR2 
subunits and four FKBP12.6 (also called 
calstabin 2) proteins. In addition, cAMP-
dependent protein kinase A (PKA), the 
protein phosphatases PP1 and PP2A, and 
the anchoring protein mAKAP6 have been 
shown to belong to the complex (Marx 
et al. 2000). Calcium release through 
RYR2 occurs in a coordinated manner, 
because RYR2 channels are functionally 
and physically coupled. Removal of the 
regulatory protein FKBP12.6 removes the 
functional but not the physical coupling. 
(Marx et al. 2001)
During exercise, the sympathetic 
nervous system stimulation leads to 
catecholaminergic activation of beta-
adrenergic receptors (Rockman et al. 
2002). These are coupled to G-proteins to 
activate the adenylyl cyclase that elevates 
REVIEW OF THE LITERATURE
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calcium release (channel openings), while 
the low affinity binding site inhibits it. 
Free magnesium inactivates the channels 
at 1 mM concentration, which is the 
physiologic level of this ion (Zucchi and 
Ronca-Testoni 1997; Copello et al. 2002). 
ATP, as well as other adenine nucleotides, 
acts as an activator of RYR2, increasing 
the channel’s open probability (Zucchi and 
Ronca-Testoni 1997).
The importance of the RYR2 channel 
is underlined by the findings that mutant 
mice lacking RYR2 develop morphological 
abnormalities in the heart tube and die 
at approximately embryonic day 10 
(Takeshima et al. 1998). In failing human 
hearts, RYR2 channels have been proposed 
to be hyperphosphorylated by PKA (Marx 
et al. 2000). This is predicted to result in 
defective function of the channels due 
to increased sensitivity to Ca2+-induced 
activation (Marks 2000; Marx et al. 2000).
Figure 4. Schematic model of the 
cardiac ryanodine receptor and 
its suggested interactions with 
triadin, junctin and calsequestrin. 
Proteins not drawn to scale. RYR2, 
ryanodine receptor type 2; CASQ2, 
cardiac calsequestrin.
Cytoplasm
SR lumen
N
C
RYR2 pore
N
C
N
C
Junctin
Triadin
CASQ2
N
C
N
C
CASQ2
RYR2
intracellular cAMP concentration, that in 
turn activates cAMP-dependent protein 
kinase A (PKA) (Brodde and Michel 
1999). As a result, RYR2 channels are 
phosphorylated by PKA. Phosphorylation of 
the RYR2 channels dissociates FKBP12.6, 
which in turn results in an increase in the 
open probability of the channel. 
Calcium, magnesium, and ATP 
modulate RYR2 channels (Valdivia 
et al. 1995). Of these, calcium is the 
physiological channel activator (Coronado 
et al. 1994; Zucchi and Ronca-Testoni 
1997). The Ca2+ dependence of the 
channel is biphasic: low (micromolar) 
cytoplasmic [Ca2+] activates the channels, 
and high (millimolar) cytoplasmic [Ca2+] 
inactivates them. The biphasic response to 
calcium has been hypothesized to result 
from the presence of both high- and low-
affinity Ca2+ binding sites in the channel: 
the high-affinity binding site stimulates 
16
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Calsequestrin 2 (CASQ2) protein is 
located inside the SR. It binds calcium 
with high capacity and moderate affinity, 
buffering Ca2+ inside the SR and preventing 
its intra-sarcoplasmic precipitation 
(Mitchell et al. 1988). Crystallization of 
the skeletal muscle isoform CASQ1 reveals 
that calsequestrin forms three domains, 
each with a thioredoxin fold (Wang et 
al. 1998). Calcium binds mostly between 
these domains and to the protein surface. 
This mechanism differs from that of other 
Ca2+-binding proteins, since most of them 
have EF-hand structures (motifs formed by 
two helixes, E and F) that mediate binding. 
The acidic carboxyterminus of CASQ2 
plays a critical role in calcium binding 
and in interactions with other proteins 
(MacLennan and Reithmeier 1998). As 
Ca2+ is bound, calsequestrin polymerizes 
into extended soluble structures (Wang et 
al. 1998).
RYR2 and CASQ2 form a complex 
through triadin and junctin (Figure 4). 
These two membrane proteins anchor 
calsequestrin molecules at the inner face of 
the junctional SR membrane (Zhang et al. 
1997). Together, RYR2, CASQ2, triadin, 
and junctin form the junctional complex 
essential for calcium-induced calcium 
release. L-type calcium channels in the 
T-tubular regions and RYR2 channels in 
the SR are located close to each other, and 
thereby the activation of RYR2 channels is 
under the tight control of L-type channels, 
resulting in the rapid and efficient coupling 
of membrane depolarization and SR Ca2+ 
release (Wier and Balke 1999). 
2 GENETIC BASIS OF INHERITED 
ARRHYTHMIC DISORDERS 
A number of familial disorders are known 
to manifest with cardiac arrhythmias. 
Symptoms of cardiac myopathies may be 
associated with structural changes in the 
heart muscle, while in other disorders, the 
heart muscle itself is intact, but its electrical 
properties are compromised. Although 
at population level these arrhythmic 
disorders are rare, their clinical importance 
is significant. They may have severe 
health consequences (syncope, ventricular 
fibrillation, sudden death) and usually affect 
young, otherwise healthy individuals.
During recent years, many genes 
underlying these fatal diseases have been 
identified, mainly through positional 
cloning strategy. Several genes remain 
unknown, however. As initial research 
has focused on diseases with high clinical 
impact, arrhythmic diseases with a milder 
phenotype or a complex inheritance have 
probably been neglected.
2.1 ELECTRIC INHERITED ARRHYTHMIAS
2.1.1 Long QT syndromes 
In 1957, Jervell and Lange-Nielsen 
described a syndrome manifesting with 
prolonged QT interval and syncopal spells 
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associated with deafness and a family 
pattern that suggests autosomal recessive 
inheritance. A few years later, it became 
apparent that patients with normal hearing 
could also suffer from these typical cardiac 
features, and that this form of the disease 
is inherited as an autosomal dominant trait 
(Ward 1964; Romano 1965).
Clinical features
Congenital long QT syndrome 
(LQTS) is characterized by a delayed 
ventricular repolarization which leads to 
prolongation of the QT interval on the 
electrocardiogram (ECG) (Chien 1999) 
(Figure 5). Other clinical features include 
T-wave abnormalities, syncopal spells, 
and torsade de pointes (twisting of the 
points) ventricular arrhythmias (Figure 5). 
These arrhythmias are typically induced by 
physical exercise or emotional stress, and 
can be fatal. The affected individuals show 
no structural abnormalities of the heart 
muscle. 
Estimates of the prevalence of 
autosomal dominant LQTS (Romano-Ward 
syndrome, RWS, OMIM 192500) range 
from 1:5 000 to 1:10 000. The autosomal 
recessive form of LQTS (Jervell and Lange-
Nielsen syndrome, JLNS, OMIM 220400), 
in which arrhythmias are associated with 
congenital deafness, is extremely rare 
(Ackerman 1998). Since many of the 
individuals affected with dominant LQTS 
are asymptomatic, this syndrome is likely 
to remain undiagnosed. The comprehensive 
set of diagnostic criteria for LQTS in use 
since 1993 takes into account the QT 
interval corrected for heart rate (QT
c
), 
morphology of the T-wave, and patient’s 
clinical and family history (Schwartz et al. 
1993). Heart-rate-corrected QT interval is 
calculated from the equation QT
c
 = QT/
RR1/2 (sec), where RR denotes the heart rate 
Figure 5. ECG strips (lead 2) demonstrating a) normal QT interval, b) prolonged QT interval, c) abnormal 
T-wave, and d) torsade de pointes ventricular arrhythmia.
a b
c d
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in beats per minute (Bazett 1920). 
Mortality estimates as high as 50% per 
ten years have been presented for LQTS 
(Moss et al. 1991; Ackerman 1998). This 
is probably an overestimate reflecting the 
fact that more severely affected individuals 
were identified in the early years of LQTS 
studies. 
Molecular genetics of LQTS
LQTS can be divided into several subtypes 
based on the mode of inheritance and 
the genetic defect underlying the disease 
(Table 1; see also for complete gene 
names). Estimates are that a third (Wichter 
et al. 2002) or even half (Moss 2003) of the 
LQTS-causing mutations have been found 
to date. Since there are many families 
in whom the phenotype does not show 
linkage to any of the known disease loci, 
it is probable that unknown loci exist even 
yet. 
LQT1 (OMIM 192500) Mutations of 
the KCNQ1 gene result in the LQT1 subtype 
of the long QT syndrome and account for 
approximately 42% of genetically defined 
LQTS (Splawski et al. 2000). More than 
one hundred mutations have been identified 
in this gene (see the Internet database 
Gene connection for the heart). KCNQ1 is 
expressed in the heart, ear, kidney, lung, and 
placenta (Wang et al. 1996a; Neyroud et al. 
1997). In Finland, the founder mutation 
G589S is detected in 30% of Finnish LQTS 
patients (Piippo et al. 2001b; unpublished). 
This mutation is located in the C-terminus 
of the protein and has a clinically mild 
phenotype. In functional studies, the 
G589S mutant subunits formed functional 
channels, but showed reduced currents 
(Piippo et al. 2001b). 
LQT2 (OMIM 152427) This subtype 
results from mutations in the HERG gene 
which is abundantly expressed in the heart 
and brain (Wymore et al. 1997). HERG 
(also called KCNH2, for potassium voltage-
gated channel, subfamily H, member 2) is 
composed of 15 exons (Itoh et al. 1998) 
and was originally described as the human 
counterpart of the Drosophila ether a-go-go 
related gene (Warmke and Ganetzky 1994). 
Heterozygous mutations in the HERG gene 
lead to the RW syndrome (Curran et al. 
1995), but some homozygous patients have 
also been described with a severe cardiac 
phenotype but without associated hearing 
loss (Hoorntje et al. 1999; this study). With 
more than 130 HERG mutations identified 
(Internet database Gene connection for the 
heart), estimates are that 45% of inherited 
LQTS is caused by mutations in this gene 
(Splawski et al. 2000). In Finland, however, 
mutations in the KCNQ1 gene appear to be 
a more frequent cause of LQTS than are 
mutations in the HERG gene (Piippo et al. 
2001b; unpublished). 
LQT3 (OMIM 603830) The SCN5A 
gene consists of 28 exons and encodes 
a voltage-gated cardiac sodium channel 
(Wang et al. 1996b). The expression of 
this gene is evident solely in cardiac tissue. 
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Mutations in SCN5A appear to be a relatively 
rare cause of LQTS, representing only 8% 
of the molecularly defined cases (Splawski 
et al. 2000). In the Finnish population, only 
one mutation has been described to date 
(Piippo et al. 2001a). This V1667I mutation 
causes a relatively mild form of LQT3, but 
when halofantrine, an antimalarial drug, 
was administered, the mutation carriers 
experienced ventricular tachycardia and a 
considerable prolongation of QT
c
 (Piippo 
et al. 2001a). 
LQT4 (OMIM 600919) In a single 
large French kindred the phenotype of 
LQTS and sinus node dysfunction was 
mapped to chromosome 4q25-27 (Schott et 
al. 1995). Recently, in the affected family 
members the ankyrin B (AnkB) gene was 
shown to harbor a mutation (Mohler et al. 
2003). AnkB is a 45-exon gene expressed in 
most cell types and coding for a membrane 
adaptor targeting numerous proteins to cell 
membrane (Mohler et al. 2002). Mutations 
in AnkB probably constitute an extremely 
rare cause of LQTS, since there have been no 
other reports of LQTS families’ phenotypes 
showing linkage to this chromosomal 
region. This gene has not been studied in 
the Finnish LQTS population.
LQT5 (OMIM 176261) and LQT6 
(OMIM 603796) are caused by mutations 
in the KCNE1 and in the KCNE2 genes. 
These genes, located only 79 kb apart, 
are transcribed from oppositely oriented 
frames. The gene product of KCNE2 is 
a 123 amino-acid auxiliary subunit for 
potassium channel KCNQ1, while KCNE3 
codes for a 103 amino-acid protein which 
possibly modulates the HERG channel 
(Abbott et al. 1999). Heterozygous 
mutations in the KCNE1 and in the KCNE2 
genes lead to the RW type of LQTS 
(Splawski et al. 1997; Abbott et al. 1999). 
Mutations in the KCNE1 and in the KCNE2 
genes account for 3% and 2% of inherited 
LQTS, respectively (Splawski et al. 2000). 
In Finland, no mutations have been detected 
in these genes to date.
LQT7 (OMIM 170390) Recently, 
mutations in the KCNJ2 gene were found in 
patients affected with Andersen syndrome 
(Tristani-Firouzi et al. 2002), a rare disorder 
characterized by prolonged QT interval, 
cardiac arrhythmias, periodic paralysis, and 
dysmorphic features. In addition, mutations 
were also detected in patients with LQTS 
and periodic paralysis (Ai et al. 2002). 
The KCNJ2 gene consists of 2 exons and 
has a mRNA of 1.3 kb in size. It encodes 
an inwardly rectifying potassium channel 
comprising two transmembrane domains 
and a pore region (Raab-Graham et al. 
1994). Variable expression and penetrance 
may account for the polymorphic clinical 
phenotype resulting from KCNJ2 mutations. 
Since many of the KCNJ2 mutation carriers 
present with prolonged QT interval, this 
gene has been labeled as the LQT7 gene 
(Tristani-Firouzi et al. 2002). 
JLNS In Jervell and Lange-Nielsen 
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syndrome, the arrhythmic symptoms 
are accompanied by congenital deafness 
(Jervell and Lange-Nielsen 1957). In 
general, the hearing defect is inherited as 
an autosomal recessive trait and the cardiac 
phenotype as an autosomal dominant trait. 
Heterozygous mutation carriers are usually 
clinically unaffected or have borderline 
prolonged ECGs. Mutations in genes 
coding for potassium channel subunits 
underlying the I
Ks
 current, namely KCNQ1 
(Neyroud et al. 1997) and KCNE1 (Tyson 
et al. 1997), lead to the JNLS phenotype. 
The rationale behind mutations in the same 
genes resulting in both RWS and JLNS is 
that KCNQ1 and KCNE1 are expressed 
abundantly also in the inner ear. They are 
involved in production of endolymph, 
the potassium-rich fluid of the inner ear 
(Neyroud et al. 1997). Complete loss of the 
channel function destroys the endolymph 
ion homeostasis, resulting in abnormal hair 
cell function and deafness. 
Although heterozygous KCNQ1 
mutations usually lead to the Romano-
Ward syndrome, and homozygous or 
compound heterozygous mutations result 
in the Jervell and Lange-Nielsen syndrome, 
some mutations differ from this pattern. In 
particular, the A300T missense mutation in 
the KCNQ1 gene has been reported to result 
in a severe cardiac phenotype but normal 
hearing in the homozygous offspring of 
heterozygous parents with normal hearing 
and no cardiac symptoms (Priori et al. 
1998). In JLNS families, some heterozygous 
carriers have clearly prolonged QT
c
 intervals 
and could therefore be classified as having 
RW syndrome (Duggal et al. 1998; Piippo 
et al. 2001b). These findings imply that no 
straightforward classification of recessive 
and dominant LQTS can be made. 
Molecular pathogenic mechanisms of 
LQTS-causing mutations
Mutations in several different genes result 
in the LQTS phenotype. At least four 
distinct mechanisms underlie the delayed 
repolarization that leads to prolonged QT 
interval: 1) Defects in the delayed rectifier 
potassium currents I
Ks
 and I
Kr
 (LQT1, 
LQT2, LQT5, LQT6) result in reduced 
outflow of potassium ions, thus lengthening 
the repolarization phase (Shalaby et al. 
1997; Splawski et al. 2000). 2) LQT3-
associated SCN5A mutants produce an 
increased sodium current by resistance 
to inactivation (Tan et al. 2003), while 
3) KCNJ2 mutations in LQT7 result in 
reduction of the inward potassium current 
I
K1
 (Ai et al. 2002). 4) The gene that causes 
LQT4 codes for the membrane-targeting 
protein ankyrin B, and accordingly the 
resultant pathogenic mechanism differs 
from that the other subtypes (Mohler et 
al. 2003). The only mutation described in 
this gene has a loss-of-function phenotype 
and thus results in the disrupted cellular 
organization of the sodium pump, Na+/Ca2+ 
exchanger, and inositol-1,4,5-trisphosphate 
receptors. 
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Several mechanisms have been 
described by which the mutations in ion 
channel genes lead to the LQTS phenotype. 
In general, mutations in potassium channel 
subunits show a loss-of-function phenotype 
resulting in reduced potassium currents 
(Roden 2001), whereas the LQTS-causing 
mutations of the SCN5A gene have a gain-
of-function effect: increasing the flow of 
sodium ions to the cell (Dumaine et al. 
1996; Tan et al. 2003).
The dominant negative effect–in 
which, when heterotetramers are formed, 
the mutant channel subunit suppresses the 
activity of wild-type subunits–is probably 
the most common mechanism leading 
Table 1. Summary of primarily electric arrhythmogenic disorders.
Disease Locus Key clinical features Gene Protein
LQT1 11p15.5 ECG abnormalities, syncope KCNQ1 K+ channel α subunit
LQT2 7q35-36 ECG abnormalities, syncope HERG K+ channel α subunit
LQT3 3p21-23 ECG abnormalities, syncope SCN5A Na+ channel α subunit
LQT4 4q25-27 ECG abnormalities, sinus node 
dysfunction
AnkB Adaptor protein
LQT5 21q22.1-22.2 ECG abnormalities, syncope KCNE1 K+ channel β subunit
LQT6 21q22.1-22.2 ECG abnormalities, syncope KCNE2 K+ channel β subunit
LQT7 17q23 Prolonged QT, periodic paralysis KCNJ2 K+ channel α subunit
JLNS1 11p15.5 Congenital deafness, cardiac 
manifestations
KCNQ1 K+ channel α subunit
JLNS2 21q22.1-22.2 Congenital deafness, cardiac 
manifestations
KCNE1 K+ channel β subunit
CPVT 1q42-43 Syncope, sudden death RYR2 Ca2+ release channel
CPVT 1p13.3-11 Syncope, sudden death CASQ2 Ca2+ binding protein
BS 3p21-23 ECG abnormalities, RBBB SCN5A Na+ channel α subunit
PCCD 3p21-23 Conduction disturbances SCN5A Na+ channel α subunit
PCCD 19q13.2-13.3 Conduction disturbances ? ?
WPW 7q36 Preexcitation PRKAG2 AMP-activated kinase γ 
subunit
AF 6q14-q16 Atrial arrhythmia ? ?
AF 10q22-q24 Atrial arrhythmia ? ?
AF 11p15.5 Atrial arrhythmia KCNQ1 K+ channel α subunit
LQT, long QT syndrome; KCNQ1, gene for potassium voltage-gated channel, KQT-like subfamily, 
member 1; HERG, human ether a-go-go-related gene; SCN5A, gene for sodium channel, voltage-gated, 
type V, alpha; AnkB, gene for ankyrin B; KCNE1, gene for potassium voltage-gated channel, Isk-related 
family, member 1; KCNE2, gene for potassium voltage-gated channel, Isk-related family, member 2; 
KCNJ2, gene for potassium inwardly rectifying channel, subfamily J, member 2; JLNS, Jervell and 
Lange-Nielsen syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; RYR2, gene for 
ryanodine receptor, type 2; CASQ2, gene for calsequestrin 2; BS, Brugada syndrome; PCCD, progressive 
cardiac conduction defect; WPW, Wolf-Parkinson-White syndrome; PRKAG2, gene for protein kinase, 
AMP-activated, gamma 2 non-catalytic subunit; AF, atrial fibrillation; RBBB, right bundle branch block; 
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to reduction in the I
Ks
 and I
Kr
 currents 
(Shalaby et al. 1997; Nakajima et al. 1998; 
Splawski et al. 2000). Some mutants do 
not form functional channels and therefore 
do not exhibit a dominant-negative effect 
(Sanguinetti et al. 1996a). The mutant 
protein can also be misfolded, subsequently 
recognized by the cellular machinery, and 
targeted to degradation pathways, thus 
never reaching the plasma membrane. 
This type of trafficking defect results from 
some KCNQ1 (Roden 2001) and HERG 
mutations (Huang et al. 2001). 
Genotype-phenotype correlation in LQTS
Most of the mutations underlying the 
LQTS phenotype have been detected in 
KCNQ1, HERG, and SCN5A genes, while 
mutations in other known LQTS genes 
appear to be rare (Internet database Gene 
connection for the heart). But does the 
locus of the causative mutation have any 
effect on patient phenotype? Indeed, it 
appears that the clinical course of LQTS 
can at least in part be predicted based on the 
underlying gene. A recent study evaluating 
647 genotyped patients was aimed at risk 
stratification in LQTS (Priori et al. 2003). 
Its results were that cumulative survival 
rate is higher among the patients carrying 
a mutation in the KCNQ1 gene than among 
those with a mutation in the HERG or 
SCN5A gene. The same study shows that 
a significant portion (36%) of KCNQ1 
mutation carriers have a normal QT
c
, 
whereas in the SCN5A group, this figure is 
only 10%. The lethality of cardiac events is 
higher in the SCN5A group than in the other 
two groups (Zareba et al. 2003). 
Gene-specific triggers have also been 
identified. Individuals carrying a mutation 
in the KCNQ1 gene have been shown 
to experience most of their symptoms 
(62%) during physical exercise, with only 
3% of their arrhythmic events occurring 
during sleep (Schwartz et al. 2001). With 
HERG and SCN5A genes, the situation 
differs: patients in these groups are more 
likely to experience cardiac events during 
rest or sleep. An auditory stimulus often 
triggers cardiac events in the HERG group 
(Jongbloed et al. 1999; Schwartz et al. 
2001), but swimming is a frequent trigger 
among KCNQ1-mutation carriers (Schwartz 
et al. 2001). Beta-blocker therapy is more 
effective among LQT1 patients than among 
LQT2 and LQT3 patients (Schwartz et al. 
2001). 
Genetic and phenotypic heterogeneity of 
LQTS
Since an increasing number of genes (to 
date, seven) and hundreds of mutations 
underlying different LQTS phenotypes 
have been detected (Table 1), it has become 
clear that a single genetic defect does not 
completely determine the phenotype of 
each patient. Variable phenotypes in related 
individuals with the same mutation suggests 
the influence of environmental factors 
and the presence of modifying genetic 
effects (Priori et al. 1999a; Moss 2003). 
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At least in the LQT1 and LQT2 subgroups, 
gender and age affect probability of cardiac 
events (Zareba et al. 2003). The reduced 
penetrance and variable expressivity 
associated with mutations in the different 
LQTS genes remain to be explained. 
2.1.2 Catecholaminergic polymorphic 
ventricular tachycardia
Catecholaminergic polymorphic ventricular 
tachycardia (CPVT, OMIM 604772), which 
is also denoted FPVT (familial polymorphic 
ventricular tachycardia), is characterized by 
episodes of bidirectional and polymorphic 
ventricular tachycardias (Leenhardt et al. 
1995) (Figure 6). Physical or emotional 
stress typically triggers the symptoms, with 
no myocardial abnormalities observed. QT 
intervals in affected subjects are normal 
or borderline prolonged. The onset of 
the disease is in adolescence or young 
adulthood. Mortality from this syndrome 
is high, reaching as high as 31% by the age 
of 30 if left untreated (Swan et al. 1999). 
Treatment with beta-adrenergic blockers 
appears to be an effective therapy (Fisher et 
al. 1999), but occasionally an implantable 
cardiac defibrillator is necessary (Swan et 
al. 1999). Table 2 shows the main clinical 
features of CPVT.
In the initial study, 30% of patients had 
a familial history of syncope or sudden 
death (Leenhardt et al. 1995). Since then, 
both autosomal dominant and recessive 
modes of inheritance have been reported. 
Our group mapped the dominant form of 
the disease to chromosome 1q42-43 (Swan 
et al. 1999), while the recessive form was 
localized in the short arm of the same 
chromosome (Lahat et al. 2001a). Recently, 
the dominant form was shown to result from 
mutations in the cardiac ryanodine receptor 
gene (this study; Priori et al. 2001), while 
Figure 6. 
Electrocardiogram 
(leads V1-V5) during 
exercise stress test 
of a 46-year-old 
male, demonstrating 
ventricular complexes 
(black arrows).
V1
V2
V3
V4
V5
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mutations in the cardiac calsequestrin gene 
were reported to underlie the recessive form 
of CPVT (Lahat et al. 2001b) (Table 1).
2.1.3 Other inherited electrical 
arrhythmias
Brugada’s syndrome (BS, idiopathic 
ventricular fibrillation, OMIM 601144) 
This is an ubiquitous disease with a 
prevalence of 1 in 2 000 in the general 
population (Antzelevitch et al. 2003). 
It is, however, more prevalent in South 
Asia (Vatta et al. 2002), where it is called 
sudden unexplained nocturnal death. For 
some unknown reason, it more often affects 
males. Symptoms include ventricular 
fibrillation and a heightened risk of cardiac 
sudden death. The ECG shows an elevated 
ST segment and shortened action potentials. 
BS can be caused by loss-of-function 
mutations of the SCN5A gene (Chen et al. 
1998), while the LQT3 phenotype results 
from gain-of-function mutations in the 
same gene, but many BS patients lack 
SCN5A mutations. Another locus has been 
mapped to chromosome 3p22-25 (Weiss 
et al. 2002) near the SCN5A gene, but no 
defective gene has yet been identified.
Progressive cardiac conduction 
defect (PCCD, OMIM 113900) is 
characterized by progressive slowing of 
the electrical conduction through the His-
Purkinje system, manifesting as widening 
of the QRS complexes. This may lead to 
atrioventricular block and sudden death. 
SCN5A missense mutations underlie PCCD 
(Schott et al. 1999), and also underlie the 
LQT3 and Brugada syndrome. Compound 
heterozygosity for two particular SCN5A 
mutations results in severe disturbances 
and degenerative changes in the conduction 
system, whereas the heterozygous carriers 
of these same mutations were asymptomatic 
(Bezzina et al. 2003). A second PCCD locus 
was localized to chromosome 19q13.2-13.3 
(Brink et al. 1995), but the actual disease-
causing gene remains unknown.
Wolff-Parkinson-White syndrome 
(WPW, OMIM 194200) is characterized 
by pre-excitation of the ventricles by 
accessory atrioventricular fibers (Al-Khatib 
Table 2. Summary of symptoms and findings in CPVT (Modified from Swan and Laitinen 2002).
Symptoms Exercise- or stress-related syncopal spells or sudden death
Resting ECG Usually normal findings
Minor QT interval prolongation possible
Electrophysiologic study Programmed electrical stimulation rarely induces ventricular tachycardia
In some patients isoproterenol infusion induces ventricular arrhythmias 
Exercise stress test and 
ambulatory ECG
Ventricular premature complexes, ventricular bigeminy, salvoes of 
polymorphic ventricular premature complexes, or non-sustained polymorphic 
ventricular tarchycardia during physical effort 
Cardiac imaging studies Usually normal findings
Localized right ventricular aneurysms or dyskinetic areas in some patients
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and Pritchett 1999). Electrocardiographic 
findings include short PR interval and 
prolonged QRS. The prevalence of WPW 
has been 1.5 to 3.1 per 1 000 individuals 
in Western countries (Gollob et al. 2001). 
Most cases are sporadic, but also familial 
occurrence with autosomal dominant 
inheritance has been reported. Clinical 
manifestations of WPW are diverse, 
since the symptoms of WPW can be 
accompanied by atrial septal defect, mitral 
valve prolapse (Al-Khatib and Pritchett 
1999), dilated cardiomyopathy (Grunig 
et al. 1998), and many other conditions. 
Approximately 10% of patients affected 
have hypertrophic cardiomyopathy (HCM), 
and the defective gene underlying WPW 
has been localized to 7q3 with linkage 
analysis in families affected with WPW 
or HCM or both (MacRae et al. 1995). 
Haplotype analysis in WPW families with 
autosomal dominant inheritance refined 
the linkage area in chromosome 7q34-36, 
and a mutation in the gene coding for the 
gamma-2 regulatory subunit of the AMP-
activated protein kinase (PRKAG2) was 
subsequently detected in two families 
(Gollob et al. 2001). The PRKAG2 protein 
modulates glucose uptake and glycolysis, 
and mutations in PRKAG2 gene lead to 
increased glycogen storage (Arad et al. 
2003). 
Atrial fibrillation (AF), a common 
cardiac arrhythmia associated with 
significant morbidity and mortality, is 
characterized by rapid and irregular 
activation of the atrium (Go et al. 2001). 
The prevalence ranges from 0.1% in adults 
younger than 55 to 9% in persons aged 
80 or older. AF can be associated with a 
number of genetic disorders, including 
hypertrophic and dilated cardiomyopathy 
and long QT syndrome type 4. Although 
AF is usually secondary to other conditions 
such as hyperthyroidism, hypertension, or 
left ventricular dysfunction, a substantial 
minority of patients have “lone AF” without 
accompanying metabolic or cardiovascular 
abnormalities, and may thus possess a 
hereditary predisposition to this disease 
phenotype. 
Autosomal dominantly inherited AF 
(OMIM 607554) has been localized to three 
distinct loci. Three families showed linkage 
to 10q22-24 (Brugada et al. 1997) and one 
family to 6q14-16 (Ellinor et al. 2003), 
but the defective gene at both of these loci 
remains unknown. A genome-wide scan in 
a four-generation family with autosomal 
dominant hereditary AF localized the 
defective gene to chromosome 11p15.5 
(Chen et al. 2003). Mutation screening of 
the positional candidate genes revealed a 
missense mutation in the KCNQ1 gene. 
In functional studies, channels harboring 
this S140G mutation showed a gain-of-
function phenotype (Chen et al. 1998). As 
mentioned above, LQTS-causing mutations 
in the same gene result in a loss-of-function 
phenotype.
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2.2 ARRHYTHMOGENIC DISORDERS 
ASSOCIATED WITH STRUCTURAL 
ABNORMALITIES
2.2.1 Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM, 
OMIM 192600) is primarily a disorder of 
the myocardium which causes distinctive 
anatomic and histologic features and can 
result in severe clinical manifestations 
(Chien 1999). Left ventricular wall 
thickening diminishes the chamber 
volumes. The myocyte arrangement is 
distorted, and the proportion of fibroblasts 
is increased, reducing the elasticity of the 
chamber walls and decreasing contractility. 
Clinical features include dyspnea, chest 
pain, atrial and ventricular arrhythmias, 
heart failure, and elevated risk of sudden 
death (Arad et al. 2002). The symptoms 
usually begin at a later age, but age of onset 
and degree of symptoms vary significantly 
(Arad et al. 2002; Towbin and Bowles 
2002). In the general population, HCM has 
a prevalence of 1 in 500 (Maron et al. 1995). 
It is estimated that more than half the HCM 
cases are familial, most often inherited as 
an autosomal dominant trait. 
It was long thought that HCM was 
purely a disease of the sarcomere, since 
mutations in genes encoding contractile 
proteins cause the disease (Seidman and 
Seidman 2001). Recently, research has 
shown that mutations in other genes also 
can lead to the HCM phenotype (Blair et 
al. 2001; Arad et al. 2002). The unifying 
feature of the consequences of the mutations 
seems to be inefficient utilization of ATP, 
leading to the increased energy cost of 
force production (Crilley et al. 2003). This 
is in line with the late onset of the disease: 
when the cell grows older, cellular energy 
production decreases, and thus a subtle 
defect in one of the components needed for 
muscle contraction begins to take its toll. 
To date, more than ten genes have been 
linked to the HCM phenotype (Table 3). 
Mutations in some of these are associated 
with extracardiac symptoms, which renders 
the classification of a phenotype such 
as HCM difficult. Mutations of cardiac 
myosin-binding protein C and β-myosin 
heavy-chain genes appear to be the most 
frequent cause of inherited HCM (Richard 
et al. 2003). Together, mutations in these 
two genes account for 82% of all HCM 
mutations identified. In Finland, mutations 
of the gene coding for cardiac myosin-
binding protein C account for 38% of 
familial HCM (Jääskelainen et al. 2002), 
whereas the β-myosin heavy chain gene 
does not constitute a significant cause of 
HCM (Jääskelainen et al. 1998).
In addition to mutations in nuclear 
genes, mutations in mitochondrial DNA 
or nuclear encoded mitochondrial proteins 
also result in hypertrophic and dilated 
cardiomyopathy. These mutations include 
deletions and point mutations in transfer 
RNA genes (Suomalainen et al. 1992; 
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Shi et al. 1999). The phenotype of the 
mitochondrial mutations often include 
symptoms of other organs (Naviaux 2000; 
Wallace 2000).
2.2.2 Dilated cardiomyopathy 
Ventricular dilatation and diminished 
contraction characterize the phenotype of 
dilated cardiomyopathy (DCM, OMIM 
115200). This disease has a prevalence 
of 1:2 500 and causes heart failure, 
serious arrhythmias, and thromboembolic 
events. The clinical course of DCM may 
be progressive, and roughly half of the 
affected individuals die within 5 years 
of diagnosis without transplantation 
(Towbin and Bowles 2002). Symptoms 
include dyspnea, palpitations, and easy 
fatigue (Grunig et al. 1998). The onset 
of symptoms is most commonly between 
the ages of 18 and 50, but children of all 
ages and the elderly can also be affected 
(Towbin and Bowles 2002). Approximately 
25 to 30% of DCM is inherited (Grunig 
et al. 1998) as an autosomal recessive, X-
linked or mitochondrial trait with reduced 
penetrance. Cardiac symptoms are often 
accompanied by symptoms in other organs 
(Table 3).
More than 15 loci for DCM have 
been identified (Table 3), but only a small 
number of causative genes have been found, 
and apparently most of the disease-causing 
mutations remain unknown. Substantial 
phenotypic and genetic variety suggests that 
yet more disease loci are likely to appear. 
Most DCM genes code for cytoskeletal, 
contractile, or inner-nuclear membrane 
proteins, while the function of the 
disease-causing gene tafazzin is unknown 
(D’Adamo et al. 1997). Many of the genes 
mutated in HCM also harbor mutations 
leading to the DCM phenotype, but the 
mutations differ (Watkins 2003). There 
appears to be a wide range of molecular 
pathogenic mechanisms underlying the 
DCM phenotype, a general feature being 
disruption of myocyte architecture or 
viability (Watkins 2003).
Intriguingly, two DCM loci, 6q12-16 
(Sylvius et al. 2001) and 10q21-23 (Bowles 
et al. 1996), overlap with the loci found to 
associate with atrial fibrillation (Brugada 
et al. 1997; Ellinor et al. 2003). As also 
the clinical phenotypes of these disorders 
overlap, it is reasonable to hypothesize that 
these diseases could share predisposing 
genes. 
2.2.3 Arrhythmogenic right ventricular 
dysplasia 
The major clinical features of 
arrhythmogenic right ventricular 
dysplasia (ARVD, OMIM 107970) are 
fibrofatty replacement of right ventricular 
myocardium and life-threatening ventricular 
arrhythmias. The incidence and prevalence 
of ARVD are unknown. However, it is 
unusually common in northeastern Italy 
(prevalence 1:1 000) (Rampazzo et al. 
1994), accounting for more than 20% of 
sudden deaths among young Italian athletes 
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(Corrado et al. 1998). ARVD is typically 
inherited as an autosomal dominant trait 
with variable penetrance. Naxos disease, 
an autosomal recessive form of this 
trait, is associated with woolly hair and 
palmoplantar keratoderma (McKoy et al. 
2000). 
Seven different loci for ARVD have 
been identified (Table 3). It is of particular 
interest that one subtype of this disease, 
ARVD2, was mapped to chromosome 
1q42-43 (Rampazzo et al. 1995), and 
affected patients had mutations in the 
gene coding for ryanodine receptor type 
2 (RYR2) (Tiso et al. 2001). The defective 
genes in Naxos disease (McKoy et al. 2000) 
and in ARVD8 (Rampazzo et al. 2002) 
have been identified for plakoglobin and 
desmoplakin, respectively. 
As most of the ARVD genes are still 
unknown, the molecular pathogenic 
mechanism underlying these phenotypes 
cannot be established. Some of the ARVD2 
mutations in the RYR2 gene are reported to 
result in reduced binding of the regulatory 
protein FKBP12.6 (calstabin 2) (Tiso et 
al. 2002). Plakoglobin and desmoplakin 
encode for proteins involved in cell-cell 
and cell-adhesion complexes (McKoy et al. 
2000) (Rampazzo et al. 2002). Most likely, 
mutations in these genes result in decreased 
integrity of cell-cell junctions which leads 
Table 3. Arrhythmogenic disorders associated with structural abnormalities.
Disease Locus Additional phenotype Defective protein Reference
HCM 1q32 None Cardiac troponin T (Thierfelder et al. 
1994)
2q24.3 None Titin (Satoh et al. 1999)
3p21 Skeletal myopathy Essential myosin light chain (Poetter et al. 1996)
7q36 Pre-excitation (WPW) AMP-activated kinase, γ 
subunit
(Blair et al. 2001)
10q24 Lactic acidosis, seizures Cytochrome C oxidase 
assembly protein COX 15
(Antonicka et al. 
2003)
11p11 None Cardiac myosin binding 
protein-C
(Watkins et al. 1995)
11p15.1 None Muscle LIM protein (Geier et al. 2003)
12q23-21 Skeletal myopathy Regulatory myosin light 
chain
(Poetter et al. 1996)
14q12 None Cardiac β myosin heavy 
chain
(Geisterfer-Lowrance 
et al. 1990)
14q12 None Cardiac α myosin lightchain (Niimura et al. 2002)
15q14 None Cardiac actin (Mogensen et al. 
1999)
15q22 None α tropomyosin (Thierfelder et al. 
1994)
19q13 None Cardiac troponin I (Kimura et al. 1997)
20q13.3 None Myosin light-chain kinase (Davis et al. 2001)
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DCM 1q21.2 Conduction disease Lamin A/C (Fatkin et al. 1999)
1q32 None Cardiac troponin T (Kamisago et al. 2000)
2q14-22 Conduction disease ? (Jung et al. 1999)
2q24.3 None Titin (Gerull et al. 2002)
2q35 Skeletal myopathy Desmin (Li et al. 1999)
3p25-22 Conduction disease ? (Olson and Keating 
1996)
4q12 None β sarcoglycan (Barresi et al. 2000)
5q33 None δ sarcoglycan (Tsubata et al. 2000)
6q12-16 None ? (Sylvius et al. 2001)
6q22.1 Heart failure Phospholamban (Schmitt et al. 2003)
6q23 Skeletal myopathy, 
conduction defect
? (Messina et al. 1997)
6q23-24 Sensorineural hearing 
loss
? (Schonberger et al. 
2000)
9q13-22 None ? (Krajinovic et al. 
1995)
10q21-23 Mitral valve prolapse ? (Bowles et al. 1996)
11q15.1 None Muscle LIM protein (Knoll et al. 2002)
14q11 None Cardiac β myosin heavy 
chain
(Kamisago et al. 2000)
15q14 None Cardiac actin (Olson et al. 1998)
15q2 None α tropomyosin (Olson et al. 2001)
17q12 None T-cap (Knoll et al. 2002)
Xp21 Skeletal myopathy Dystrophin (Muntoni et al. 1993)
Xq28 Short stature, 
neutropenia
Tafazzin (D’Adamo et al. 1997)
ARVD 1q42-43 None Ryanodine receptor 2 (Tiso et al. 2001)
2q32 None ? (Rampazzo et al. 
1997)
3p23 None ? (Ahmad et al. 1998)
6q24 None Desmoplakin (Rampazzo et al. 
2002)
10p14-12 None ? (Li et al. 2000a)
14q12-22 None ? (Severini et al. 1996)
14q23-24 None ? (Rampazzo et al. 
1994)
Naxos 
disease
17q21 Palmoplantar 
keratoderma
Plakoglobin (McKoy et al. 2000)
HCM, hypertrophic cardiomyopathy; WPW, Wolf-Parkinson-White syndrome; DCM, dilated 
cardiomyopathy; ARVD, arrhythmogenic right ventricular dysplasia.
In addition, mitochondrial inheritance of HCM and DCM has been reported.
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to disruption of the cellular architecture in 
the tissue. 
3 ION CHANNEL DISEASES 
Ion channel diseases (”channelopathies”) 
represent a relatively new field of inherited 
diseases, although more than 400 different 
ion channels exist (Gargus 2003). Voltage-
gated ion channels generating electrical 
signals in cells share several structural 
similarities but differ in their ion selectivity 
and tissue specificity (Terlau and Stuhmer 
1998). As described below, mutations in 
essentially the same ion channels produce 
distinct but yet predictable phenotypes in 
different tissues. A typical feature of ion 
channel diseases, phenotypic heterogeneity, 
can also be observed: a wide range of 
phenotypes can be produced with allelic 
mutations in ion channel genes (Barchi 
1998). 
3.1 RYANODINE RECEPTOR DEFECTS–
EXAMPLES OF DISEASES OF 
CALCIUM METABOLISM
Except for the cardiac RYR2 channel, 
there exist two other isoforms of ryanodine 
receptors: RYR1 is expressed mainly 
in the skeletal muscle, whereas RYR3 
has a wide expression pattern, although 
originally identified in the brain. A high 
level of structural similarity exists between 
different RYRs (Tunwell et al. 1996). 
RYR1 and RYR2 especially are very 
homologous, sharing 87% of amino acids 
in their putative transmembrane segments 
and showing an overall identity of 66% 
(Otsu et al. 1990). Differences between 
the amino acid sequences are reflected in 
the structure of the proteins (Sharma et al. 
1998) and are probably responsible for the 
functional differences–for example, their 
differing sensitivities to Ca2+ activation/
inactivation and to Mg2+ inhibition. 
Mutations in the RYR1 gene cause 
malignant hyperthermia (MH) and central 
core disease (CCD) (see McCarthy et al. 
2000 for review). MH is a pharmacogenetic 
disorder of skeletal muscle. In susceptible 
individuals, administration of halogenated 
anesthetics will trigger a possibly fatal 
clinical MH episode characterized by 
hypermetabolism, muscle rigidity, rapid 
increase in body temperature, lactic and 
respiratory acidosis, and tachycardia 
(MacLennan 2000). CCD exhibits major 
clinical variability, but common symptoms 
include hypotonia and proximal muscle 
weakness. Histological examination 
shows amorphous central regions (cores) 
in type 1 muscle fibers with a relative lack 
or complete absence of mitochondria in 
these core areas. The loss of mitochondria 
is probably caused by continuous high 
cytoplasmic Ca2+ concentration. Since 
mitochondria participate in removal of 
the excess calcium, this leads to Ca2+ 
overload in the mitochondria and their 
subsequent destruction (Missiaen et al. 
2000). CCD is closely related to MH, 
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and CCD patients are normally treated as 
MH-susceptible. Mutant RYR1 channels 
display an increased sensitivity to caffeine 
and a significantly reduced calcium release 
(Monnier et al. 2000). This supports the 
hypothesis of channels releasing Ca2+ 
inadequately, which leads to depletion of 
the Ca2+ stores. 
All hitherto identified RYR1 mutations 
are clustered in three distinct regions of the 
gene in exons 2 to 18, 39 to 46, and 98 to 105 
(McCarthy et al. 2000), corresponding to the 
cytoplasmic N-terminal portion, the central 
portion encompassing the FKBP12.6-
binding region and the C-terminal portion 
comprising the transmembrane domains. 
Interestingly, the recently identified RYR2 
mutations also seem to cluster in exactly 
the same areas (this study; Priori et al. 2001; 
Tiso et al. 2001; Bauce et al. 2002; Marks 
et al. 2002; Priori et al. 2002). Intuitively, 
two plausible explanations exist: either 
mutations elsewhere in the channel protein 
are not well tolerated, or these regions play 
a particularly functional role. 
Mutations in the RYR1 and RYR2 genes 
result in phenotypes with serious clinical 
manifestations. Intriguingly, no reports 
of any neurological symptoms among 
patients with the RYR2 mutations have 
appeared even though RYR2 is the major 
ryanodine receptor isoform expressed in 
the brain (McPherson and Campbell 1993). 
The gene coding for RYR3 has a wide 
expression pattern and is yet to be linked to 
any clinical phenotype. This renders RYR3 
an extremely interesting candidate gene for 
multisystemic neuromuscular disorders. 
3.2 DISEASES OF POTASSIUM AND 
SODIUM SIGNALING
The ion channel genes underlying LQTS 
phenotypes belong to three gene families. 
The KCNQ family comprises four genes, 
all linked to clinical phenotypes. Mutations 
in the genes coding for the muscle isoforms 
KCNQ2 and KCNQ3 underlie benign 
familial neonatal convulsions–a generalized 
transient epilepsy of the newborn (Hubner 
and Jentsch 2002). These two channel 
subunits assemble to form heteromeric 
channels. The KCNQ4 gene is expressed in 
the outer hair cells of the inner ear (Cooper 
and Jan 1999). These cells’ function is 
increased sensitivity of sound perception. 
Mutations in the KCNQ4 gene result in 
autosomal dominantly inherited childhood-
onset deafness (Kubisch et al. 1999). 
The LQTS-causing genes KCNE1 and 
KCNE2 code for small auxiliary subunits 
of voltage-gated potassium channels and 
belong to the KCNE gene family. The third 
member of this family is KCNE3, which is 
abundantly expressed in skeletal muscle. 
A single missense mutation in the KCNE3 
gene is associated both with hypokalemic 
and hyperkalemic periodic paralysis 
(Abbott et al. 2001). 
The sodium channel gene SCN5A 
harbors mutations resulting in various 
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arrhythmic diseases including LQTS, 
Brugada syndrome, and progressive cardiac 
conduction defect. Other members of the 
SCN family have also been characterized. 
Mutations in the SCN1A and SCN2A genes 
underlie the phenotype of generalized 
epilepsy with febrile seizures in childhood 
and sometimes also afebrile seizures in 
adulthood (Escayg et al. 2000; Sugawara 
et al. 2001; Hubner and Jentsch 2002). 
The SCN4A gene underlies a number of 
neuromuscular entities: paramyotonia 
congenita, potassium-aggravated myotonia, 
hypo- and hyperkalemic periodic paralysis, 
and malignant hyperthermia (Gargus 
2003). 
4 MOLECULAR DIAGNOSIS IN 
INHERITED ARRHYTHMIC 
DISEASES 
Identification of individuals at risk for 
an arrhythmia or sudden cardiac death 
is clinically important, but, variable 
phenotype and age of onset as well as 
reduced penetrance impede the clinical 
diagnosis in many arrhythmic disorders. 
Increased knowledge of the genetic basis 
of inherited arrhythmias has supplied the 
means for accurate detection of patients at 
risk. Molecular genetic testing can provide 
diagnostic and prognostic information 
that complements clinical examination 
in assessment for the diagnosis. When a 
genetic defect causing a familial disease 
is identified, the pathophysiological 
substrate is conclusively determined, and 
unequivocal identification of gene carriers 
becomes possible (Priori 1997).
4.1 Indications and limitations in 
genetic screening 
In the diagnosis or management of patients 
when exact diagnosis is hindered by reduced 
penetrance or variable phenotype, or when 
the clinical course varies markedly by 
genotype or mutation type, DNA analysis 
is particularily likely to be helpful (Vincent 
2001). A major question for future research 
is related to the screening of individuals 
for mutations and polymorphisms that 
may predispose to induction of arrhythmia 
(Behr and McKenna 2003). The feasibility 
of genetic screening is, however, of concern 
(Vincent 2001; Marian and Roberts 
2003). Optimally, to permit unequivoical 
diagnosis of all affected individuals with a 
certain phenotype, all the genes and their 
mutations causing the disease should be 
known. Unfortunately, this is not the case 
for any inherited disease. 
A recent paper reports the screening of 
nine hypertrophic cardiomyopathy-causing 
genes in 197 unrelated probands (Richard 
et al. 2003). The disease-causing mutation 
was identified in 63% of the patients, and 
62% of the mutations were novel. This 
situation resembles that of other arrhythmic 
disorders, including LQTS (Chiang and 
Roden 2000; Richard et al. 2003), and 
emphasizes the need for comprehensive 
screening of the complete sequence of 
known causal genes in each individual, 
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rather than screening restricted to known 
mutations or particular parts of genes 
(Marian and Roberts 2003; Richard et al. 
2003). 
Due to the variable phenotype and 
penetrance of LQTS, genetic diagnosis 
is likely to become particularly useful. 
The corrected QT interval (QT
c
) is one of 
the major clinical criteria of LQTS, but a 
marked overlap exists in the QT
c
 intervals 
of affected and unaffected individuals 
(Vincent et al. 1992; Saarinen et al. 1998; 
Chiang and Roden 2000). Mutation 
carriers with normal or borderline QT
c
 can 
be at risk for syncope and sudden death 
(Piippo et al. 2001b), especially when 
predisposed to QT-prolonging drugs (Priori 
et al. 1999b). Identification of these non-
penetrant individuals with genetic analysis 
is therefore important. 
4.2 Different strategies in molecular 
diagnosis
Linkage analysis (Terwilliger and Ott 1994) 
can be used for DNA diagnosis if the locus 
for the disease has already been determined 
(Eng and Vijg 1997). This method is 
applicable only when DNA samples at least 
of the parents and unaffected siblings of 
the patient in interest are available (Priori 
1997). 
As faster and more cost-effective 
mutation screening methods have 
developed, the DNA samples of 
ungenotyped probands can be screened 
for mutations in multiple known disease 
genes. However, mutation screening is 
still time- and money consuming, and in 
most laboratories, a complete screening 
of several genes cannot be provided as a 
routine diagnostic method. In addition, 
some probands may have mutations in 
unknown genes, or detection of a specific 
mutation of a particular gene may fail, due 
to limitations in analytic techniques (Li et 
al. 2000b; Vincent 2001). If the mutation 
is however known in a family, family 
members can undergo mutation detection-
based DNA diagnosis. 
In Finland, the peculiar population 
history of Finns has provided a unique 
opportunity to utilize founder mutations 
in molecular diagnosis of LQTS. Because 
the founder mutation KCNQ1-Fin accounts 
for approximately 30% of all LQTS 
cases, a single low-cost test performed on 
individuals suspected to be affected with 
LQTS identifies a considerable portion of 
the disease carriers (Piippo et al. 2001b). 
Since the syndrome is relatively rare, 
population-level screening would most 
likely be fruitless.
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AIMS 
The aim of this study was to clarify the genetic background of two severe ventricular 
arrhythmic diseases: catecholaminergic polymorphic ventricular tachycardia (CPVT) 
and long QT syndrome (LQTS), with special emphasis on elucidation of the molecular 
pathogenesis of CPVT, as no information was available on the causative gene, its 
mutations, or their functional consequences. Due to its central role in regulation of 
cardiac repolarization, HERG was considered a particularly important LQTS gene, and no 
information existed on possible Finnish-type HERG mutations at the start of the present 
study.
The specific aims were:
1. Fine-map the CPVT locus on chromosome 1q42-43.
2. Identify the CPVT gene and characterize the disease-causing mutations.
3. Study the functional properties of the genetic defects causing CPVT.
4. Survey the HERG gene for mutations and polymorphisms in Finnish LQTS 
patients. Develop diagnostic tests for routine detection of the gene mutations 
predisposing to life-threatening arrhythmias.
PATIENTS AND METHODS
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1 PATIENTS AND CONTROLS
At the commencement of this study, 
two Finnish families affected with 
catecholaminergic polymorphic ventricular 
tachycardia (CPVT) had been identified and 
the disease locus mapped to chromosome 
1q42-43 (Swan et al. 1999). The phenotypic 
characteristics of CPVT included exercise-
induced ventricular premature complexes 
during a stress test. In addition, the patients 
had experienced polymorphic ventricular 
tachycardias, and many of the families 
had a history of unexplained sudden 
death. No structural or histopathological 
abnormalities of the myocardium existed. 
In Study I, two additional Finnish families 
suspected to carry the same disease were 
studied by haplotype analysis to confirm 
the diagnosis and to delineate the disease 
locus. These four families comprised study 
group 1, which underwent screening of the 
complete coding region of the RYR2 gene. 
Study group 2 consisted of 12 new probands 
whose DNA had not been analyzed 
previously. In this group, we analyzed 
approximately half of the coding region of 
the RYR2 gene. While the screening of the 
RYR2 gene was in progress in study group 
2, clinical studies revealed seven new 
Finnish families (group 3) affected with 
CPVT. In Study III, the samples of groups 2 
and 3 (n = 19) were screened for mutations 
in the CASQ2 gene. The two amino acid 
polymorphisms that were identified in the 
CASQ2 gene were also determined in a 
cohort of 185 unrelated probands with long 
QT syndrome (LQTS), in which previous 
molecular studies had failed to detect 
disease-causing mutations.
In Study V, 40 Finnish probands 
with congenital LQTS were screened 
for mutations in the HERG gene, which 
had been previously shown to underlie 
LQTS. The patients fulfilled at least two 
of the following diagnostic criteria: 1) 
prolonged heart-rate-corrected QT interval 
(> 440 ms), 2) presence of syncopal 
spells or documented torsade de pointes 
tachycardia or both, and 3) family history 
of LQTS or sudden death. In the same 
study, LQTS patients (n = 81) carrying 
the KCNQ1-Fin mutation (Piippo et al. 
2001b) were genotyped for HERG K897T 
polymorphism. Study IV concentrated on a 
severely affected LQTS proband who was 
also included in Study V.
When a mutation was detected in 
a proband, all his or her relatives and 
an appropriate number of control DNA 
samples were also studied for the mutation. 
The control cohort comprised 300 Finnish 
blood donors from the Helsinki area. The 
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sex ratio of this cohort was 1:1, and the 
cohort contained only adults. Informed 
consent was obtained from the study 
subjects, and the Ethics Review Committee 
of the Department of Medicine, University 
of Helsinki, approved this study.
2 MOLECULAR GENETIC STUDIES
The methods are described in more detail in 
the original publications I to V. 
2.1 DNA EXTRACTION AND POLYMERASE 
CHAIN REACTION
Genomic DNA was extracted from 
peripheral lymphocytes, either by the 
standard phenol extraction method 
(Blin and Stafford 1976) or the salting-
out method with the PureGene DNA 
Purification Kit (Gentra, Minneapolis, 
MN). The polymerase chain reactions 
(PCR) (Mullis et al. 1986) were performed 
under varying conditions and with intronic 
primers, whenever possible.
2.2 MUTATION SCREENING
Sequencing PCR-amplified DNA fragments 
were purified and directly sequenced with 
BigDye Terminator (Applied Biosystems, 
Foster City, CA) chemistry based on the 
use of di-deoxynucleotides in controlled 
termination of the elongation reaction 
(Sanger et al. 1977). The fragments were 
analyzed with the ABI377 Prism automated 
sequencer (Applied Biosystems).
Denaturing high-performance 
liquid chromatography (dHPLC) An 
application of the heteroduplex formation 
method, dHPLC, was used in mutation 
screening in Studies I and III. The 
optimal melting curves for PCR-amplified 
DNA fragments were calculated with 
Wavemaker software (Transgenomics, 
Omaha, NE), and fragments were run with 
the DNA-sep column and Wave 3500A 
Nucleic Acid Fragment Analysis system 
(Transgenomics).
2.3 MICROSATELLITE ANALYSIS
Several databases of different genome 
centers (including the Sanger Centre, the 
Whitehead Institute, and The Genetic 
Location Database) were searched 
for multiallelic, highly polymorphic 
microsatellite markers located in the 
areas of interest. Primer sequences came 
from The Genome Database. Genomic 
fragments were amplified with primers 
containing a fluorescent label in the 5’ 
primer. After pooling, these fragments were 
run on ABI377, and results were analyzed 
with GenScan and Genotyper computer 
programs (Applied Biosystems). See 
Internet references for detailed addresses of 
the genome centers.
2.4 LINKAGE AND HAPLOTYPE ANALYSIS
Pairwise linkage analyses were performed 
with the MLINK and ILINK options of the 
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FASTLINK v 4.1P package. Haplotypes, 
which were used to study the relatedness 
of the families carrying the HERG-Fin 
mutation and fine mapping of the CPVT 
locus, were constructed manually.
2.5 BIOCOMPUTING
Several sequence databases, computer 
programs, and search tools were utilized 
in this study (see Internet references for 
details). Of these, the following were 
particularly valuable: the BLAST2 computer 
program served for the determination of the 
genomic organization of CPVT candidate 
genes coding for the G-protein γ
4
 subunit 
(GNG4, 2 coding exons), the type-3 
muscarinic receptor (CHRM3, 1 exon), 
and the cardiac ryanodine receptor (RYR2, 
105 exons). PCR primers were designed 
with the Primer3-program. The Clustal W-
alignment program was used in comparing 
different homologs of the proteins of 
interest. Evolutionary conservation of 
amino acids altered by these mutations was 
deduced based on these alignments. 
2.6 SPECIFIC DETECTION METHODS FOR 
DNA ALTERATIONS
Upon identification of each nucleotide 
alteration, a specific detection method was 
set up (Table 4). This method was then 
utilized in the screening of relatives of the 
mutation/polymorphism carriers and of the 
DNA samples of at least 100 healthy control 
individuals. The majority of these methods 
were based on restriction endonuclease 
digestion, since many mutations alter the 
recognition site of a certain enzyme. When 
a mutation did not result in a change of 
restriction pattern, an artificial recognition 
site was generated by primer-induced 
restriction analysis (PIRA) (Haliassos et 
al. 1989). Solid-phase minisequencing 
(Syvänen et al. 1990) and heteroduplex 
analysis (White et al. 1992) both were used 
in detection of single-nucleotide alterations, 
while two mutations were detected with 
direct sequencing.
3 FUNCTIONAL ANALYSES
Site-directed mutagenesis was utilized 
in creating constructs for the functional 
studies. RYR2 mutations P2328S, Q4201R, 
and V4653F were separately introduced 
to partial RYR2 cDNA in the pBS vector 
with the Chameleon double-stranded, 
site-directed mutagenesis kit (Stratagene, 
La Jolla, CA). The fragments containing 
the desired mutations were subsequently 
subcloned to full-length RYR2 cDNA in the 
pCMV5 vector. The L552S HERG mutation 
was introduced to HERG cDNA in the 
pcDNA3 plasmid with the QuickChange 
site-directed mutagenesis kit (Stratagene).
Each of the mutant RYR2 cDNAs was 
co-transfected to HEK-293 cells with 
FKBP1B cDNA coding for the regulatory 
protein FKBP12.6. These transfections 
were performed by the Ca2+ phosphate 
precipitation method. Microsomes 
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containing recombinant RYR2 channels 
were isolated and in vitro phosphorylated 
with the protein kinase A catalytic 
subunit. Single-channel recordings were 
performed under voltage-clamp conditions 
(Gaburjakova et al. 2001). Data were 
analyzed with Fetchan software (Axon 
Instruments, Union City, CA). 
Transfections of HERG-L552S mutants 
to COS7 cells were made with Effectene 
Transfection Reagent (Qiagen, Valencia, 
CA). Whole-cell membrane currents were 
measured with the EPC-9 amplifier and 
Pulse/Pulsefit software (HEKA, Lambrecht, 
Germany).
4 STATISTICAL ANALYSES
Fisher’s exact and the χ2 test served for 
comparison of categorical variables. 
Analysis of variance (ANOVA) taking 
relatedness into account was used in Study 
V, which compared the QT
c
 intervals of 
Table 4. Specific detection methods to detect mutations and polymorphisms identified in Studies 
I and III-V.
Gene Alteration Detection Allele2
RYR2 Mutation V2306I TaaI mutant
P2328S HaeIII wild-type
Q4201R PvuII wild-type
V4653F NcoI (PIRA1) wild-type
P4902L HaeIII mutant
R4959Q BspI wild-type
Polymorphism G1885E sequencing -
Q2958R BsrGI (PIRA1) wild-type
13682+67 C>T NlaIII mutant
HERG Mutation R176W SmaI mutant
P451L AluI mutant
L552S NcoI (PIRA1) mutant
Y569H RsaI mutant
G584S AluI mutant
G601S SfiI wild-type
T613M sequencing -
453delC sequencing -
1631delAG heteroduplex-analysis -
Polymorphism K897T BstUI (PIRA1) mutant
CASQ2 Polymorphism T66A Hin6I mutant
V76M minisequencing -
1PIRA, primer-induced restriction analysis used in the detection
2denotes whether the wild-type or mutant allele is cleaved by the restriction enzyme
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KCNQ1-Fin carriers with different HERG 
K897T genotypes. Unpaired Student’s t-
test was used in comparing the means of 
in vitro experimental results. A P-value 
of < 0.05 was considered statistically 
significant.
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Figure 7. Pedigrees of families affected with CPVT. Linkage and haplotype analyses as well as screening of 
the whole coding region of the RYR2 gene were performed in families 1-4. In families 5-7, approximately 
half of the RYR2 gene and the complete coding region of the CASQ2 gene were studied. 
RESULTS
1 IDENTIFICATION OF THE GENE 
CAUSING DOMINANT CPVT
1.1 FINE-MAPPING THE CPVT LOCUS (I)
When this study was initiated, two families 
(Figure 7, families 1 and 2) affected with 
autosomal dominantly inherited CPVT 
had been identified, and a genome-wide 
scan had assigned the disease locus to 
chromosome 1q42-43 (Swan et al. 1999). 
In the present study, linkage analysis 
in two novel CPVT families revealed 
maximum pairwise lod scores of 2.43 
(family 3) and 1.06 (family 4) at marker 
D1S2670, thus suggesting linkage to the 
locus identified earlier. The combined lod 
score value of all the families was 8.23 at 
the same marker. Haplotype analysis in 
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1.3 IDENTIFICATION OF RYR2 MUTATIONS 
IN CPVT PATIENTS (I, III) 
As the next step in search of the gene 
underlying CPVT, the candidate gene 
ryanodine receptor type 2 (RYR2) was 
screened for mutations in the probands of 
families 1 to 4 (I). Genetic analysis of the 
complete coding region (105 exons) of RYR2 
revealed three nucleotide substitutions. 
These alterations were predicted to result 
in amino acid changes P2328S, Q4201R, 
and V4653F (Figure 9A), in families 1, 4, 
and 3. Several individuals in each of the 
families were shown to carry the respective 
mutation (Table 5). No causative mutation 
was detected in family 2, in which a LOD 
score of 2.07 was demonstrated at marker 
D1S2670 (Swan et al. 1999).
In Study III, 12 new CPVT probands 
were enrolled for analysis of the RYR2 
gene. The screening was concentrated 
in regions of the RYR2 gene proposed 
in Study I to be pathophysiologically 
significant and shown to harbor mutations. 
Figure 8. Summary of 
informative haplotypes 
delineating the disease 
locus in chromosome 
1q42-43. Box: disease 
locus. Families shared no 
common haplotype.
all the four CPVT families showed that 
the families shared no common haplotype. 
However, recombinations in families 1 and 
3 delineated the disease locus as between 
markers D1S235 and D1S2670 (Figure 8). 
This narrowed the linkage region from 9 
centiMorgans (cM) (Swan et al. 1999) to 
approximately 1.5 cM, which, according to 
the Ensembl Genome Browser, corresponds 
to approximately 2.5 megabases. 
1.2 SCREENING OF CANDIDATE GENES (I)
The narrowed linkage area contained 
several genes. GNG4 (Kalyanaraman et 
al. 1998), coding for a G-protein subunit γ, 
and CHMR3 (Shi et al. 1999), coding for 
a muscarinic receptor ion channel, were 
selected for mutation screening based on 
their position and function. The samples 
from the four original probands were 
screened for mutations in these genes by 
direct sequencing. No sequence alterations 
were detected compatible with a pathogenic 
role.
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Three novel point mutations were revealed 
(Figure 9A): V2306I, P4902L, and 
R4959Q. The missense mutation V2306I 
was detected in the affected son of the 
proband, but not in her parents. Paternity 
was confirmed by haplotype analysis. 
P4902L and Q4959Q were present only 
in the respective probands. All the six 
RYR2 gene alterations described in Studies 
I and III co-segregated with the disease 
phenotype in the corresponding families, 
but were absent from control individuals. 
In addition to the six mutations, two amino 
acid polymorphisms were detected (Table 
9, Discussion). 
1.4 PHENOTYPIC CHARACTERISTICS OF 
RYR2 MUTATIONS (I, II)
Some of the phenotypic features of RYR2 
mutation carriers are depicted in Table 5. 
In general, most of the mutation carriers 
had experienced syncopes associated with 
physical or emotional stress. On exercise 
testing, when heart rates exceeded an 
individual threshold, isolated unifocal and 
multifocal ventricular premature complexes 
appeared. Penetrance of the mutations was 
not complete, as two carriers of the P2328S 
mutation were asymptomatic. Most patients 
had experienced their first symptoms 
around the age of 10 years, but age of onset 
ranged from 6 to 40.
Figure 9a) A schematic view of RYR2 protein containing all mutations described until 2/2004. Mutations 
described in this study (●), mutations described by Priori et al (Priori et al. 2001; Priori et al. 2002) ( ), 
Tiso et al (Tiso et al. 2001), and Bauce et al (Bauce et al. 2002) (□). The mutations with bold font result 
in CPVT phenotype. Mutations with normal font have been described as associating with ARVD2, or the 
associated phenotype is ambiguous. b) Approximate location of all the reported CASQ2 mutations by Lahat 
et al (□) (Lahat et al. 2001b) and Postma et al ( ) (Postma et al. 2002). The polymorphisms (●). Location 
of the predicted Ca2+ binding region is indicated. 
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Table 5. Clinical characteristics of RYR2 mutation carriers (mean, or mean ± SD values).
V2306I P2328S Q4201R V4653F P4902L R4959Q
Family no. 5 1 4 3 6 7
Carriers (n) 2 16 3 10 1 1
Age, yr 14 ± 13 29 ± 14 56 ± 16 45 ± 20 56 60
Resting heart rate, 
     bpm
47 71 ± 12 57 78 ± 16 41 72
Threshold heart 
     rate, bpm
105 129 ± 17 NA 133 ± 20 100 100
QT
c
, ms 445 430 ± 20 448 440 ± 50 380 438
Sudden deaths (n)
     at age < 35 yr 
     in family
0 4 4 5 0 0
SD, standard deviation; NA, not available.
Threshold rates at which nonsustained 
ventricular arrhythmias occurred during 
the exercise test did not significantly differ 
between families 1 and 3 (Table 5). Other 
families were too small to permit any 
genotype-phenotype correlations (Figure 
7).
1.5 FUNCTIONAL PROPERTIES OF 
MUTANT RYR2 CHANNELS (II)
The mutant RYR2 channels, when 
compared to the wild-type channels, 
showed several functional abnormalities. 
When phosphorylated, the mutant 
P2328S, Q4201R, and V4653F channels 
showed a significant increase in open 
probability, gating frequency, and mean 
open time values. Long-lasting open states, 
not characteristic of wild-type RYR2 
channels, were also observable. Unlike 
phosphorylated wild-type channels, the 
phosphorylated homotetrameric mutant 
RYR2 channels showed resistance to 
inhibition by incremental concentrations 
of Mg2+, the physiologic inhibitor of RYR2 
channels. As magnesium concentration 
increased, the activity of wild-type channels 
became completely inhibited, whereas the 
mutant channels showed a significantly 
higher activity and required higher Mg2+ 
concentrations for inhibition. 
Since CPVT is inherited as an autosomal 
dominant trait, it was pertinent to co-
express the wild-type RYR2 cDNA with 
mutant RYR2 cDNAs. Open probability, 
gating frequency, and resistance to 
inhibition by Mg2+ resembled those of the 
homotetrameric mutant channels. In short, 
after PKA phosphorylation, the hetero- 
and homotetrameric mutant channels 
display a gain-of-function abnormality. 
This is consistent with a “leaky” channel 
phenotype and a defect in regulation by the 
physiologic inhibitor Mg2+.
Recently, the 1,4-bentzothiazepine 
derivative (JTV519) was shown to inhibit 
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progression of heart failure in a dog model, 
and it was proposed that this may involve 
regulation of RYR2 activity (Yano et al. 
2003). Accordingly, the effect of JTV519 
on the activity of PKA phosphorylated 
P2328S mutant channels was also 
examined. JTV519 treatment resulted in 
normalization of channel activity and re-
binding of FKBP12.6. This indicates that 
this experimental drug may rescue the gain-
of-function defect in P2328S channels. 
2 SCREENING OF THE CASQ2 
GENE IN THE FINNISH CPVT 
PROBANDS (III)
Since mutations of calsequestrin type 
2 (CASQ2) were shown to result in the 
recessive (Lahat et al. 2001b), and possibly 
also the dominant form of CPVT (Postma 
et al. 2002), the gene appeared to be a 
reasonable candidate in the Finnish CPVT 
families. Screening of the complete coding 
region of the CASQ2 gene (11 exons) 
revealed a sample from a 42-year-old CPVT 
proband to be heterozygous for two amino 
acid changes, T66A and V76M (Figure 
9B). Subcloning of the corresponding 
PCR product into a plasmid and its 
subsequent sequencing demonstrated that 
both aberrations were present in the same 
allele. The affected son and mother of the 
proband, as well as his unaffected daughter 
were heterozygous for both T66A and 
V76M. Seven other CPVT probands were 
heterozygous for T66A, but V76M was 
detected in none of the 18 other probands 
studied. Both of these alterations were also 
detected in the control cohort. No other 
significant alterations were identified. 
Comparison in LQTS probands and 
Table 6. Genotype and allele frequencies for the two CASQ2 polymorphisms.
CPVT indexes (n = 19) LQTS (n = 177) Blood donors (n = 265)
T66A Genotypes TT 57.8% 57.1% 51.3%
AT 42.1% 34.5% 40.4%
AA 0% 8.5% 8.3%
Alleles Allele T 78.9% 74.3% 71.5%
Allele A 21.2% 25.7% 28.5%
V76M Genotypes VV 94.7% 94.6% 94.8%
VM 5.3% 5.4% 5.2%
MM 0% 0% 0%
Alleles Allele V 97.4% 97.3% 97.4%
Allele M 2.6% 2.7% 2.6%
All differences statistically non-significant
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blood donors of the frequencies of the 
two polymorphisms alone (Table 6) 
and the resulting haplotypes showed no 
significant differences in allele or genotype 
frequencies.
3 SURVEY OF THE HERG GENE IN 
FINNISH LQTS PATIENTS 
3.1 IDENTIFICATION OF PRIVATE HERG 
MUTATIONS AND THE HERG-FIN 
FOUNDER MUTATION (IV, V)
Direct sequencing of the complete coding 
region of the HERG gene in 39 LQTS 
probands revealed a total of nine mutations 
and one amino acid polymorphism (Figure 
10). Eight of these mutations, two deletions 
and six point mutations, were each found 
in one family alone (Table 7). Nucleotide 
change T1655C, predicted to result in 
substitution of leucine 552 by serine 
(L552S), was detected in the heterozygous 
state in four families. In addition, one 
pedigree consisted of two LQTS families, 
both having its own separate proband. 
In this family, the parents of the nuclear 
family were heterozygous for the L552S 
mutation, while their two daughters were 
homozygous for L552S. 
All nine mutations co-segregated in the 
families with the disease phenotype and 
were absent from DNA samples of at least 
100 blood donors. 
In order to construct disease-associated 
haplotypes, microsatellite markers adjacent 
to the HERG gene locus were analyzed in 
all six families shown to carry the HERG 
L552S mutation. A common haplotype 
was present in all affected probands, 
thus providing evidence for a founder 
mutation. The affected grandparents of the 
homozygous individuals originated from 
the same commune in Lapland, whereas the 
ancestors of the other families were from 
eastern Finland.
3.2 PHENOTYPIC CHARACTERISTICS OF 
HERG MUTATION CARRIERS (IV, V)
Most HERG mutation carriers showed 
a marked prolongation of QT interval 
Extracellular
Intracellular
T613M
del453C L552S
Y569H
1631delAG
K897T
T601SG584S
R176W
P451L
NH2
COOH
Figure 10. The 
approximate 
location of HERG 
mutations (●) and 
polymorphism (□). 
Finnish founder 
mutation L552S 
underlined.
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compared to that of non-carriers (Table 7), 
but phenotypic variation even amongst the 
carriers of a single mutation was evident. 
In the case of the P451L mutation, none 
of the carriers had QT
c
 exceeding 440 ms. 
However, the proband and her affected 
sister had experienced syncopal spells, 
suggesting that this is a disease-causing 
mutation. Of the 45 carriers with the 
private mutations other than L552S, 16 
were symptomatic.
In the one family with the homozygous 
L552S carriers, the unrelated heterozygous 
parents were asymptomatic, while both 
their homozygous daughters were severely 
affected; one of them died at age 4. The 
mean QT
c
 of the heterozygous L552S 
carriers was significantly higher than that of 
the family members without the mutation. 
In the absence of any drug treatment, the 
QT
c
 values of the homozygous L552S 
carriers were 677 ms and 513 ms.
Of the 35 L552S carriers 25 (71%) were 
asymptomatic. Of the ten symptomatic 
mutation carriers, nine were women. Of 
symptomatic patients, 90% experienced 
symptoms while at rest. Symptomatic 
mutation carriers had a mean QT
c
 of 500 ± 
59 ms, whereas the asymptomatic carriers 
had 452 ± 34 ms and noncarriers 412 ± 
23 ms. These differences were highly 
significant; in ANOVA analysis the p value 
between all groups was < 0.001. The p value 
between symptomatic and asymptomatic 
carriers was < 0.001.
3.3 FUNCTIONAL PROPERTIES OF THE 
HERG-L552S MUTATION IN VITRO (IV)
When the HERG protein containing the 
L552S mutation was transiently expressed 
in COS7 cells, it produced functional 
channels, with robust currents similar in 
Table 7. Main clinical features of families affected with HERG gene mutations (mean, or mean ± SD 
values). 
453delC R176W P451L 1631delAG L552S1 Y569H G584S G601S T613M
Carriers (n) 19 6 4 1 35 1 10 3 1
Non-
carriers (n) 
32 10 10 1 43 4 8 12 11
Age, y
 carriers 33 ± 21 39 ± 23 34 ± 23 52 35 ± 18 16 42 ± 20 32 ± 15 28 ± 20
 non-
carriers
45 ± 18 41 ± 17 38 ± 25 76 36 ± 16 34 ± 13 36 ± 24 42 ± 25 28 ± 20
QT
c
 carriers 470 ± 42 463 ± 42 421 ± 16 488 466 ± 47 512 465 ± 21 531 ± 45 536
 non-
carriers
419 ± 20 408 ± 23 411 ± 30 461 412 ± 23 423 ± 14 417 ± 23 418 ± 27 413 ± 26
Symptomatic 
patients (n)
4 2 2 1 10 1 4 1 1
1Only individuals heterozygous for L552S mutation included.
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amplitude to those generated by the HERG-
wt construct. However, L552S displayed a 
marked increase in the rate of activation and 
deactivation. Such an increased deactivation 
rate may result in lower channel activity at 
the end of the repolarization phase.
3.4 COMMON AMINO ACID 
POLYMORPHISM IN THE HERG 
GENE (V)
In addition to several mutations, screening 
of the HERG gene revealed a common 
nucleotide alteration, A2690C, predicted 
to result in the amino acid polymorphism 
K897T. Population frequencies, as 
determined in a sample cohort of healthy 
blood donors, were 0.84 for allele A and 
0.16 for allele C. 
To study the possible phenotypic effects 
of K897T polymorphism, 170 KCNQ1-Fin 
carriers from 28 families were screened for 
this polymorphism. KCNQ1-Fin carriers 
with the HERG T897T genotype had a 
slightly lower mean QT
c
 value than did 
individuals with the K897K and K897T 
genotypes, and gender-specific analysis 
indicated that this difference was present 
in women only. In ANOVA analysis 
taking family relatedness into account, 
this difference was no longer significant, 
however.
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Long QT syndrome (LQTS) and 
catecholaminergic polymorphic ventricular 
tachycardia (CPVT) share common 
features: syncopal spells, absence of 
structural myocardial aberrations, a usually 
autosomal dominant pattern of inheritance, 
and risk of sudden death in youth. Initially, 
CPVT was considered an incomplete 
(”forme fruste”) subtype of LQTS, because 
triggering factors and patient age resemble 
those described in LQTS, in the absence of 
an unequivocal QT interval prolongation. 
However, meticulous cardiological and 
genetic analyses have revealed that 
these diseases differ both clinically and 
molecularly.
1 IDENTIFICATION OF GENES 
UNDERLYING CPVT
1.1 MUTATIONS OF THE RYANODINE 
RECEPTOR GENE IN DOMINANT CPVT
This study aimed at identification of the 
disease-causing gene of catecholaminergic 
polymorphic ventricular tachycardia 
(CPVT). First, the location of the disease 
gene was delineated by construction of a 
dense panel of microsatellite markers for 
the chromosomal region in 1q42-43. These 
markers were then utilized in haplotype 
analysis, which led to the notable reduction 
in linkage area. This facilitated the selection 
of candidate genes for further analysis. As 
screening of the candidate genes TWIK-1 
(Swan et al. 1999), GNG4, and CHMR3 
revealed no significant alterations, the 
gene coding for ryanodine receptor type 2 
(RYR2) remained as the primary candidate. 
Since the RYR2 gene is one of the largest 
known human genes (cDNA of 15.5 kb, 
105 exons), the screening was initiated with 
an indirect method (dHPLC). However, it 
was subsequently considered necessary 
to sequence the whole coding region of 
the RYR2 gene in all the four probands 
enrolled in the study. In Study I, RYR2 
mutations were identified in three of the 
four probands. 
Simultaneously, RYR2 mutations were 
reported in Italian families affected with 
CPVT (Priori et al. 2001). Interestingly, 
Italian probands affected with ARVD2, a 
variant form of ARVD previously mapped 
to the same chromosomal region (Rampazzo 
et al. 1995), also carried mutations in RYR2 
gene (Tiso et al. 2001). 
It is unclear whether CPVT and ARVD2 
represent two distinct diseases or a single 
one with variable expression. ARVD2 
patients often present with fibro-fatty 
replacement of the myocardium and discrete 
myocardial atrophy, but considerable 
DISCUSSION
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H.sapiens RYR2 ---LSVDDAKLQGAGEEEAKGGKRPKEGLLQMKLPEPVKLQMCLLLQYLCDCQVRHRIEA 1924
O.cuniculusR YR2 ---PSVEDTKLEGAGEEEAKVGKRPKEGLLQMKLPEPVKLQMCLLLQYLCDCQVRHRIEA 1924
M.musculus RYR2 ---ISIEDAKLE--GEEEAKGGKRPKEGLLQMKLPEPVKLQMCLLLQYLCDCQVRHRIEA 1923
H.sapiens RYR3 ---TQVEEKAVE---AGEKAGKEAPVKGLLQTRLPESVKLQMCELLSYLCDCELQHRVEA 1825
H.sapiens RYR1       ETAQEKEDEEKEEEEAAEGEKEEGLEEGLLQMKLPESVKLQMCHLLEYFCDQELQHRVES 1957
H.sapiens RYR2       LVSKGYPDIGWNPVEGERYLDFLRFAVFCNGESVEENANVVVRLLIRRPECFGPALRGEG 2339
O.cuniculus RYR2     LVSKGYPDIGWNPVEGERYLDFLRFAVFCNGESVEENANVVVRLLIRRPECFGPALRGEG 2340
M.musculus RYR2      LVSKGYPDIGWNPVEGERYLDFLRFAVFCNGESVEENANVVVRLLIRRPECFGPALRGEG 2339
H.sapiens RYR3       LLAKGYPDVGWNPIEGERYLSFLRFAVFVNSESVEENASVVVKLLIRRPECFGPALRGEG 2236
H.sapiens RYR1       LVAKGYPDIGWNPCGGERYLDFLRFAVFVNGESVEENANVVVRLLIRKPECFGPALRGEG 2372
H.sapiensRYR2        YILEFDGGSRG-KGEHFPYEQEIKFFAKVVLPLIDQYFKNHRLYFLSAASRPLCSGGHAS 2997
O.cuniculusRYR2      YILEFDGGSRS-KGEHFPYEQEIKFFAKVVLPLIDQYFKNHRLYFLSAASRPLCSGGHAS 2998
M.musculusRYR2       YILEFDGGSRS-KGEHFPYEQEIKFFAKVVLPLIDQYFKNHRLYFLSAASRPLCTGGHAS 2997
H.sapiensRYR3        FIAHLEAIVSSGKTEKSPRDQEIKFFAKVLLPLVDQYFTSHCLYFLSSPLKPLSSSGYAS 2893
H.sapiensRYR1        FIAHLEAVVSSGRVEKSPHEQEIKFFAKILLPLINQYFTNHCLYFLSTPAKVLGSGGHAS 3032
H.sapiens RYR2       VNEGGEKEKMELFVNFCEDTIFEMQLAAQISESDLNERSANKEESEK-----ERPEEQGP 4231
O.cuniculus RYR2     VNEGGEKEKMELFVNFCEDTIFEMQLAAQISESDLNERSANKEESEK-----ERPEEQGP 4232
M.musculus RYR2      VNEGGEKEKMELFVNFCEDTIFEMQLAAQISESDLNERLANKEESEK-----ERPEEQAP 4231
H.sapiens RYR3       VNEGGEQEKMELFVNFCEDTIFEMQLASQISESDSADRPEEEEEDEDSSYVLEIAGEEEE 4132
H.sapiens RYR1       VNEGGEAEKMELFVSFCEDTIFEMQIAAQISEPEGEPETDEDEGAGAAEAGAEGAEEGAA 4280
H.sapiens RYR2       QPSEDDIKGQWDRLVINTQSFPNNYWDKFVKRKVMDKYGEFYGRDRISELLGMDKAALDF 4679
O.cuniculus RYR2     QPSEDDIKGQWDRLVINTQSFPNNYWDKFVKRKVMDKYGEFYGRDRISELLGMDKAALDF 4681
M.musculus RYR2      QPSEDDIKGQWDRLVINTQSFPNNYWDKFVKRKVMDKYGEFYGRDRISELLGMDKAALDF 4679
H.sapiens RYR3       QPSEDDIKGQWDRLVINTPSFPNNYWDKFVKRKVINKYGDLYGAERIAELLGLDKNALDF 4584
H.sapiens RYR1       QPEDDDVKGQWDRLVLNTPSFPSNYWDKFVKRKVLDKHGDIYGRERIAELLGMDLATLEI 4751
H.sapiens RYR2       AIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGNDYFDTVPHGFETHTLQEHNLANYL 4919
O.cuniculus RYR2     AIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGNDYFDTVPHGFETHTLQEHNLANYL 4921
M.musculus RYR2      AIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGNDYFDTVPHGFETHTLQEHNLANYL 4919
H.sapiens RYR3       AIIQGLIIDAFGELRDQQEQVREDMETKCFICGIGNDYFDTTPHGFETHTLQEHNLANYL 4822
H.sapiens RYR1       AIIQGLIIDAFGELRDQQEQVKEDMETKCFICGIGSDYFDTTPHGFETHTLEEHNLANYM 4990
H.sapiens RYR2       FFLMYLINKDETEHTGQESYVWKMYQERCWEFFPAGDCFRKQYEDQLN 4967
O.cuniculus RYR2     FFLMYLINKDETEHTGQESYVWKMYQERCWEFFPAGDCFRKQYEDQLN 4969
M.musculus RYR2      FFLMYLINKDETEHTGQESYVWKMYQERCWEFFPAGDCFRKQYEDQLN 4967
H.sapiens RYR3       FFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLG 4870
H.sapiens RYR1 FFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLS 5038
V2306I P2328S
Q4201R
V4653F
P4902L
R4959Q
G1885E
Q2958R
Figure 11. Alignment of the human RYR2 protein with RYR2 proteins from other species and human 
ryanodine receptor isoforms. Only relevant parts of the proteins are included. Mutations and polymorphisms 
(italics) identified during the present study in bold with a gray background in the amino acid sequence.
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interfamilial variability exists (Rampazzo 
et al. 1995). In the Finnish CPVT patients, 
the left and right ventricular dimensions as 
well as systolic and diastolic functions were 
normal, with the exception of two cases in 
family 4, who showed minor local bulging 
of the right outflow tract. There appears to 
be no evident correlation between location 
of mutation and resulting phenotype.
In Study III, the samples from 12 
CPVT probands were screened for RYR2 
mutations. Three point mutations were 
identified, each present in a distinct family. 
In the Finnish CPVT population, of the 
16 probands studied, six (38%) showed 
RYR2 mutations. Because nine of the ten 
remaining families were insufficiently large 
to accommodate linkage studies, it was 
impossible to judge whether a mutation 
located in the regulatory regions or introns 
of the RYR2 gene, or another totally different 
gene, underlie the CPVT phenotype in 
these families. In one family (Family 2, 
Figure 7), linkage was established to the 
same chromosomal region, but sequencing 
of the entire coding region of the RYR2 
gene, as well as the other candidate genes 
GNG4, CHMR3, and TWIK-1, revealed no 
significant alterations. 
1.2 FUNCTIONAL AND PHENOTYPIC 
PROPERTIES OF RYR2 MUTATIONS
Each of the RYR2 mutations detected in this 
study alters an evolutionarily conserved 
amino acid residue (Figure 11). With the 
exception of the original families in our 
linkage study (Swan et al. 1999; Study 
I), most of the RYR2 mutations identified 
until now have occurred in small pedigrees 
(Priori et al. 2001; Priori et al. 2002). This 
may reflect reduced survival and unrealized 
reproduction of the mutation carriers. Since 
the identification of individuals affected 
with CPVT is difficult, and sudden deaths 
occur frequently among affected subjects 
if they receive inadequate treatment, this 
explanation is plausible.
After the detection of mutations in the 
RYR2 gene, several groups have studied 
their functional consequences in order 
to clarify the pathological mechanism 
underlying the clinical phenotypes. The 
results of these studies have been somewhat 
contradictory. 
In the first study published on this 
topic, the mutation R4496C was introduced 
in the mouse RYR2, equivalent to the 
human CPVT-causing mutation R4497C 
(Jiang et al. 2002). In ryanodine-binding 
studies, single-channel recordings and 
single-cell Ca2+ imaging experiments, the 
mutant displayed enhanced basal activity, 
further demonstrated by replacement of 
the arginine with glutamate, a negatively 
charged amino acid. Thus, a positive charge 
at this particular position appeared to be 
important for stabilizing the closed state 
of the channel at low Ca2+ concentrations. 
These authors suggest that the increased 
activity of RYR2 lowers the critical SR 
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Ca2+ concentration at which spontaneous 
calcium release occurs, and that this is the 
mechanism by which the enhanced basal 
activity leads to ventricular arrhythmia.
As RYR2 mutations appear to underlie 
both entirely electric disorders (CPVT) 
and disorders associated with structural 
abnormalities (ARVD2), the functional 
differences between these mutations were 
studied in yeast two-hybrid experiments 
(Tiso et al. 2002). These mutations are 
located in the central area of the channel 
encompassing the binding region for the 
regulatory protein FKBP12.6 (Marx et 
al. 2000). The results of Tiso et al (2002) 
suggest that some of the phenotypic 
variability may be explained by the 
differing effects that these mutations 
exert on FKBP12.6 binding. According 
to their results, CPVT mutations seemed 
to increase and ARVD2 mutations to 
reduce FKBP12.6 binding to RYR2. Since 
binding of FKBP12.6 increases the open 
probability of RYR2 channels, they suggest 
that CPVT mutations do not significantly 
alter the cytoplasmic calcium levels while 
ARVD2 associated mutations increase 
RYR2-mediated calcium release in to the 
cytoplasm. 
Quite opposing results come from a 
recent study addressing the functional 
properties of three mutations underlying 
CPVT (Wehrens et al. 2003). Mutations 
generated in the human RYR2 gene were 
expressed in mammalian a cell line, after 
which, the channels were used in single-
channel recordings. All three mutants 
displayed reduced affinity to FKBP12.6, 
and, after PKA phosphorylation, increased 
channel activity compared to that of wild-
type channels. PKA phosphorylation of 
the channels occurs in vivo during exercise 
(Marks 2000), in line with the phenotype of 
affected patients showing symptoms only 
during physical or emotional stress. 
The mechanism proposed by 
Wehrens et al (2003) is challenged by 
a study in which the CPVT-associated 
RYR2 mutations S2246L, N4104K, 
and R4497C were expressed in HL-1 
cardiomyocytes (George et al. 2003). At 
rest, the phenotypic characteristics of 
the cells expressing the mutant channels 
were indistinguishable from the wild type. 
When the RYR2 channels were activated 
by mechanistically different RYR agonists 
(caffeine and 4-chloro-m-cresol) or by 
beta-adrenergic stimulation, Ca2+ release 
was augmented significantly more through 
the mutant channels than through the wild 
type channels. The RYR2-FKBP12.6 
complex was severely disrupted after beta-
adrenergic stimulation, but no difference 
appeared in the FKBP12.6 dissociation rate 
between the mutant and wild type channels 
(George et al. 2003). These results indicate 
that the defect in Ca2+ release is FKBP12.6 
independent.
Our functional experiments performed 
with the RYR2 channels containing P2328S, 
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Q4201R, and V4653F mutations were 
consistent, with a pathogenic mechanism 
similar to that suggested by Wehrens et al 
(2003). We observed the same phenotype 
of “leaking” channels in all RYR2 channels 
studied, and thus the mutations probably 
resulted in global destabilization of the 
large channel complex rather than specific 
disruptions of various functional domains. 
In addition, our studies demonstrate that 
the mutated channels have a decreased 
sensitivity to inhibition by Mg2+, an 
important endogenous channel modulator. 
Our results with the experimental 
drug JTV519 demonstrate a molecular 
mechanism where JTV519 enhances 
the affinity of RYR2 for FKBP12.6 and 
rescues the gain-of-function phenotype 
of the mutant channels. These results thus 
provide a basis for targeted drug treatment 
of exercise-induced cardiac arrhythmias. 
In conclusion, several studies have 
focused on revealing the molecular 
pathogenic mechanisms of the specific 
RYR2 mutations underlying the 
phenotypes of CPVT and ARVD2. Results 
of these studies, however, do not agree. It is 
therefore necessary to obtain more detailed 
data on the structure-function aspects of 
RYR2 channels in order to understand 
how the mutations result in augmented 
intracellular Ca2+ release. 
Very recent findings suggest that 
mutations in the RYR2 gene may also 
underlie the phenotypes of hypertrophic 
and dilated cardiomyopathy (Cui et al. 
2003; Furino et al. 2003), which underlines 
the importance of the ryanodine receptor 
in cardiac myocytes. Different mutations 
appear to have very different outcomes, 
implying that alterations in the RYR2 gene 
may result in numerous cardiac phenotypes 
showing both electric and structural 
characteristics. One can hypothesize that 
this may reflect the differential functional 
effects of the mutations: some mutations 
may result in transient elevation of 
cytoplasmic calcium concentration and 
thus lead to an electric disorder like CPVT. 
Other mutations may cause more prolonged 
changes in calcium homeostasis, resulting 
in structural abnormalities of the cardiac 
muscle, as in hypertrophic and dilated 
cardiomyopathy.
1.3 CASQ2–THE SECOND GENE FOR 
CPVT
Soon after the identification of RYR2 
mutations in CPVT patients, the autosomal 
recessive form of CPVT was characterized 
and the disease gene localized to 
chromosome 1p13-21 (Lahat et al. 2001a). 
All the affected individuals belonged to 
the same Bedouin tribe, and their parents 
were often cousins. The phenotype of the 
affected individuals was severe, with high 
mortality. Average age of onset was 7.8 ± 
4 years, a figure markedly lower than in the 
dominant form (Swan and Laitinen 2002). 
Subsequent analysis of candidate genes 
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located in the 1p13-21 region revealed a 
single homozygous missense mutation in 
the CASQ2 gene in all the affected patients 
(Lahat et al. 2001b). Heterozygous mutation 
carriers were clinically unaffected. The 
CASQ2 gene encodes a protein located in 
the sarcoplasmic reticulum and functioning 
as a calcium buffer. The CASQ2 protein 
is associated physically with RYR2 
through interaction with junctin and triadin 
(Zhang et al. 1997). Of the three additional 
mutations in the CASQ2 gene have been 
reported (Postma et al. 2002), two were 
found to segregate in an autosomal 
recessive manner. The third mutation, 
however, showed a possible autosomal 
dominant mode of inheritance.
Genetic analysis of the complete coding 
region of the CASQ2 gene in 19 Finnish 
CPVT probands disclosed two amino 
acid polymorphisms but no apparently 
causative mutations. This indicates that 
this gene plays a minor if any role in the 
molecular pathogenesis of CPVT in the 
Finnish patients. The two novel amino 
acid polymorphisms detected, T66A and 
V76M, were relatively common in a cohort 
of healthy blood donors, and between the 
control and patient groups their allele, 
genotype or haplotype frequencies did not 
differ. Therefore, they most likely represent 
innocent genetic polymorphisms.
2 HERG ALTERATIONS IN LQTS 
FAMILIES
2.1 POINT MUTATIONS AND SMALL 
DELETIONS
In this study, the complete coding region of 
the HERG gene was screened for mutations 
by direct sequencing. Nine mutations, 
seven missense mutations and two small 
deletions, were detectable in families 
affected with LQTS (Table 7). Three of 
the point mutations (Y569H, G601S, 
and T613M) had occurred de novo in the 
proband or in a parent of the proband, and 
two of these (G601S and T613M) also 
occur in other populations (Akimoto et al. 
1998; Jongbloed et al. 1999). This region, 
encoding for the pore-forming portion of 
the protein, may thus represent a mutational 
“hot spot” in the HERG gene.
The clinical phenotype of those 
individuals affected by the private HERG 
gene mutations described in this study 
shows marked variation. For example, 
none of the carriers of the P451L mutation 
had a prolonged QT
c
 interval, while the 
individuals carrying the 453delC mutation 
had a mean QT
c
 of 470 ± 42 ms. More 
than a third of the mutation carriers were 
symptomatic. As for the HERG-Fin 
founder mutation, the mean QT
c
 interval 
of the symptomatic heterozygous mutation 
carriers was significantly longer than 
that of the asymptomatic carriers and 
noncarriers. The spectrum of the phenotype 
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of the heterozygous HERG-Fin carriers was 
wide, however, ranging from asymptomatic 
patients to those who had experienced 
recurrent syncopal spells.
Each of the HERG point mutations 
identified alters an amino acid conserved in 
evolution, a fact revealed when the amino 
acid sequence of the HERG ion channel 
was compared with those of homologous 
channels from other species (Figure 12). For 
example, the HERG-Fin (L552S) mutation 
substitutes a leucine that is conserved not 
only in mammals but also in Drosophila 
melanogaster. 
In functional studies, the Finnish 
founder mutation L552S displayed a 
marked increase in both activation and 
inactivation rates, when compared to wild-
H.sapiens           NEDGAVIMFILNFEVVMEKDMVGSPAHDTNHRGPPTSWLAPGRAKTFRLKLPALLALTAR 176
O.cuniculus         NEDGAVIMFILNFEVVMEKDMVGSPARDTNHRGPPTSWLAPGRAKTFRLKLPALLALTAR 159
R.norvegicus        NEDGAVIMFILNFEVVMEKDMVGSPAHDTNHRGPSTSWLASGRAKTFRLKLPALLALTAR 176
M.musculus          NEDGAVIMFILNFEVVMEKDMVGSPAHDTNHRGPSTSWLASGRAKTFRLKLPALLALTAR 176
D.melanogaster      QTQETPLWLLLQVAPIRNE----------------------------------------- 139
H.sapiens           LLLVIYTAVFTPYSAAFLLKETEEGPPATECGYACQPLAVVDLIVDIMFIVDILINFRTT 474
O.cuniculus         LLLVIYTAVFTPYSAAFLLKETEEGPPAPECGYACQPLAVVDLIVDIMFIVDILINFRTT 459
R.norvegicus        LLLVIYTAVFTPYSAAFLLKETEDGSQAPDCGYACQPLAVVDLLVDIMFIVDILINFRTT 476
M.musculus          LLLVIYTAVFTPYSAAFLLKETEDGSQAPDCGYACQPLTVVDLIVDIMFIVDILINFRTT 476
D.melanogaster      LCLTFYTAIMVPYNVAFKNKTSEDVS-----------LLVVDSIVDVIFFIDIVLNFHTT 292
H.sapiens           RLVRVARKLDRYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLG 590
O.cuniculus         RLVRVARKLDRYSEYGAAVLLLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLG 575
R.norvegicus        RLVRVARKLDRYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSHIGWLHNLG 592
M.musculus          RLVRVARKLDRYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSHIGWLHNLG 592
D.melanogaster      RLGRVVRKLDRYLEYGAAMLILLLCFYMLVAHWLACIWYSIG-RSDADNGIQYSWLWKLA 411
H.sapiens           DQIGKPYNSSG--------LGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSI 642
O.cuniculus         DQMGKPYNSSG--------LGGPSIKDKYVTGLYFTFSSLTSVGFGNVSPNTNSEKIFSI 627
R.norvegicus        DQIGKPYNSSG--------LGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSI 644
M.musculus          DQIGKPYNSSG--------LGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSI 644
D.melanogaster      NVTQSPYSYIWSNDTGPELVNGPSRKSMYVTALYFTMTCMTSVGFGNVAAETDNEKVFTI 471
H.sapiens           RQ--------------RKRKLSFRRRTDKDTEQPGEVSALG--PGRAGAG--PSSRGRPG 924
O.cuniculus         RQ--------------RKRKLSFRRRTDKDTEQPGEVSALG--PGRAGAG--PSSRGRPG 909
R.norvegicus        RQ--------------RKRKLSFRRRTDKDTEQPGEVSALGQGPARVGPG--PSCRGQPG 928
M.musculus          RQ--------------RKRKLSFRRRTDKDTEQPGEVSALGQGPARVGPG--PSCRGQPG 928
D.melanogaster      RRKNEPQLPQNQDHLVRKIFSKFRRTPQVQAGSKELVGGSGQSDVEKGDGEVERTKVLPK 771
R176W
P451L
L552S Y569H G584S
G601S T613M
K897T
Figure 12. Amino acid alterations predicted to result from the HERG point mutations and polymorphism 
(italics) detected compared with homologous proteins from four different species. Only relevant parts of the 
amino acid sequence are illustrated. Mutations and polymorphism are in bold and a with gray background.
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type channels. Increase in deactivation rate 
is expected to reduce conductance during 
terminal action potential repolarization 
and therefore to prolong the repolarization 
phase.
The functional properties of the HERG 
channel with the missense mutation G601S 
have been studied in HEK-293 cells and 
in Xenopus oocytes (Furutani et al. 1999). 
This mutant showed defective protein 
trafficking, with reduced current amplitude, 
but did not suppress the function of the 
wild-type subunit in a dominant negative 
manner. The T613M mutation has also been 
functionally characterized (Huang et al. 
2001). When expressed alone in Xenopus 
oocytes, the mutant channel did not 
produce any detectable current. When the 
mutant channel subunit was co-expressed 
with the wild-type subunit, a dominant 
negative effect and defective trafficking to 
the cell membrane could be observed. 
These three examples: increased 
deactivation rate, defective trafficking to 
the cell membrane, and dominant negative 
effect, illustrate the diverse mechanisms by 
which the mutations can lead to the LQTS 
phenotype. This could in part explain the 
variability in clinical phenotype between 
various mutations. 
Recently, an inherited short QT interval 
was described in two families (Gaita et al. 
2003). The patients exhibited a QT
c
 interval 
of < 300 ms, and the families shared a 
history of sudden deaths. Two distinct 
point mutations, both resulting in the same 
amino acid change N588K, were identified 
in the HERG gene (Brugada et al. 2004). 
The pathological mechanism by which 
this mutation leads to the shortening of 
QT interval, a totally different phenotype 
than in other HERG mutations, is a gain-
of-function abnormality (Brugada et al. 
2004). 
2.2 PHENOTYPIC EFFECTS OF K897T 
POLYMORPHISM
The effect of the K897T polymorphism 
on myocardial repolarization, tested in 
a random middle-aged population (226 
men/187 women) (Pietilä et al. 2002), 
indicates that the K897T polymorphism 
appears to have a gender-related effect on 
certain components of QT interval. Women 
homozygous for the wild-type allele had 
shorter total ventricular repolarization 
(QT
cmax
) and longer QT
c
 measured at 
lead V2 than did women carrying the 
polymorphism. 
A recent study further explored the 
phenotypic effects of this polymorphism 
both in vitro and in vivo (Paavonen et al. 
2003). When expressed in HEK-293 and 
COS cells, the channel containing the 897T 
allele showed reduced surface expression 
and increased inactivation, which were 
proposed to result in reduced macroscopic 
currents. The effect of this polymorphism 
was also investigated in a cohort of 261 
KCNQ1-Fin carriers who underwent an 
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exercise stress test. No difference in QT
c
 
interval was observable between the groups 
when all patients were included in the 
analysis or when men and women were 
considered separately. However, with only 
the patients who had prolonged QT interval 
(QT
c
 > 440 ms) at rest (n = 39) included, 
a difference in QT interval dynamics 
occurred. During exercise, the patients 
with the K897T and T897T genotypes had 
longer QT intervals than did those with the 
K897K genotype (Paavonen et al. 2003).
Despite many attempts to delineate 
the physiopathological significance of the 
HERG K897T polymorphism, it appears 
that further studies are needed to elucidate 
its exact phenotypic effects. 
3 IMPLICATIONS FOR MOLECULAR 
DIAGNOSIS IN THE VENTRICULAR 
ARRHYTHMIA DISEASES CPVT 
AND LQTS 
CPVT has an almost complete penetrance 
and a high mortality rate (Lahat et al. 
2001a; Swan and Laitinen 2002). Two 
genes have recently been identified that 
underlie this life-threatening disease (this 
study; Lahat et al. 2001b). In LQTS, caused 
by one of at least seven different genes 
(Moss 2003), the penetrance varies, and 
many mutation carriers are asymptomatic 
(Priori et al. 1999b; Piippo et al. 2001b). 
In both LQTS and CPVT, identification of 
a genetic defect underlying the disease has 
practical consequences. Early molecular 
diagnosis permits effective advice and drug 
treatment and can therefore prevent sudden 
death (Priori 1997; Moss et al. 2000).
Exact molecular diagnosis in LQTS 
is of paramount importance. It identifies 
asymptomatic mutation carriers who may 
be at risk for arrhythmias (Priori et al. 
1999b), so that accurate and personalized 
information about gene-specific risks such 
as sports or medication can be provided. 
For example, swimming is a particular risk 
factor in LQT1 type of LQTS (Schwartz et 
al. 2001), whereas sudden loud noises such 
as alarm clocks should be avoided by the 
LQT2 type (Wilde et al. 1999; this study). 
The penetrance of LQTS mutations 
can be very low. For example, our study 
demonstrates that more than 70% of the 
carriers of the HERG L552S mutation are 
asymptomatic. Genetic testing in families 
affected with LQTS mutations may 
therefore seem questionable. However, 
subtle genetic defects may predispose to 
drug-induced arrhythmias (Priori et al. 
1999b). This suggests that even though 
the mutation may seem benign, it can 
predispose to serious arrhythmias if a QT 
interval-prolonging drug is administered to 
the patient. 
In CPVT, onset of symptoms is 
usually in adolescence (Swan and Laitinen 
2002). Only two Finnish mutation 
carriers were non-penetrant at the age 
of 15 years or older without manifesting 
ventricular  arrhythmias.  Since the 
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Table 8. Present status for occurrence of the mutations in RYR2 and HERG genes identified in this study. 
Gene Mutation Coding effect Location in the channel Families (n) Carriers (n)
Non-
carriers (n)
RYR2 V2306I G6916A cytoplasmic 1 2 12
P2328S C6928T cytoplasmic 1 17 30
Q4201R A12602G transmembrane regions 1 3 22
V4653F G13957T transmembrane regions 1 10 26
P4902L C14705T transmembrane regions 1 1 36
R4959Q G14876A transmembrane regions 1 1 3
HERG 453delC frameshift truncated protein 1 36 38
R176W C526T cytoplasmic 1 7 11
P451L C1352T S2 1 5 11
L552S T1655C S5 12 91 131
1631delAG frameshift truncated protein 1 1 1
Y569H T1705C S5 1 1 4
G584S G1750A S5-pore 1 16 19
G601S G1801A S5-pore 1 3 12
T613M C1838T pore 1 1 12
26 194 368
first symptom of CPVT can be lethal, 
presymptomatic diagnosis is of utmost 
importance. Established mutation carriers 
are adequately monitored and advised to 
avoid competitive sports and to take beta-
adrenergic-blocking drugs. Beta-blocking 
therapy seems to be effective in preventing 
malignant arrhythmias, as there have 
been no sudden cardiac deaths among the 
Finnish CPVT patients since the patients 
were recruited to this study. In one patient, 
a cardiac defibrillator has been implanted 
due to non-responsiveness to drug therapy.
Since the six mutations in RYR2 and 
nine mutations in HERG described here 
were identified, several more carriers 
of these particular mutations have been 
molecularly diagnosed. Table 8 summarizes 
the situation in February 2004. Of note is 
the number of HERG-Fin carriers: a total 
of 12 families carry this mutation. In all, 
the KCNQ1-Fin (Piippo et al. 2001b) 
and HERG-Fin mutations account for 
approximately 64% of the molecularly 
defined LQTS cases in Finland. Simple 
PCR-based assays are routinely used in our 
laboratory to screen these two mutations in 
all new LQTS probands, and when positive, 
in their family members as well.
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4 CONTINUING SEARCH FOR 
ARRHYTHMIA GENES
Over the last decade, a large amount of 
information of genes predisposing to 
inherited arrhythmia diseases has been 
provided through meticulous clinical and 
genetic studies. The recent completion of 
a draft sequence of the human genome has 
revolutionized the process of disease gene 
identification, as availability of the genomic 
sequence enables exact localization of 
microsatellite markers and candidate genes 
as well as computational identification 
of previously unknown genes. Many 
LQTS probands still lack identification 
of a mutation in any of the seven known 
LQTS genes. Furthermore, only 38% of 
the Finnish CPVT probands had a mutation 
in the RYR2 gene and none in the CASQ2 
gene. Inevitably, more arrhythmia genes are 
likely to be identified, and many hitherto 
insufficiently studied ion channel genes are 
good candidates. 
Indeed, there are several promising 
candidate genes encoding for ion channels. 
The gene encoding the skeletal muscle 
L-type calcium channel (CACNA1S) 
harbors mutations in families affected 
with malignant hyperthermia (Monnier et 
al. 1997), thus establishing a second MH 
locus. Mutations leading to hypokalemic 
periodic paralysis have also been identified 
in the same gene (Ptacek et al. 1994). But, 
the cardiac L-type calcium channel gene 
(CACNA1C) has as yet been linked to no 
clinical phenotype (Gargus 2003). A similar 
situation exists for the tissue isoforms 
of the sarco/endoplasmic reticulum Ca2+ 
ATPase (SERCA). Mutations in the skeletal 
muscle isoform SERCA1, encoded by 
ATP2A1 gene, result in Brody’s disease, a 
skeletal myopathy (MacLennan 2000). The 
isoform SERCA2, encoded by the ATP2A2 
gene, has two splice variants: SERCA2b is 
expressed in the skin and harbors mutations 
leading to Darier’s disease, a skin disorder 
characterized by warty papules and plaques 
in seborrheic areas, and distinctive nail 
abnormalities (Sakuntabhai et al. 1999), 
while the cardiac isoform SERCA2a has 
yet to reveal a pathogenic allele. 
While these genes represent obvious 
candidates for the arrhythmic diseases, 
recent studies have shown that even 
some less likely candidates should not be 
ignored. The LQT4 gene turned out to be 
a membrane adaptor protein (Mohler et 
al. 2003). Hypertrophic cardiomyopathy 
results also from mutations in genes other 
than sarcomere protein-coding (Blair 
et al. 2001). Careful clinical evaluation 
and phenotyping of affected patients and 
their family members is necessary for 
identification of new inherited disease 
entities. In addition, alternative approaches 
to gene identification will most likely be 
needed, as diseases with reduced penetrance 
and of variable phenotype are difficult to 
study with conventional linkage analyses 
requiring large pedigrees. Accordingly, 
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homology analysis revealed a previously 
unidentified potassium ion channel gene 
(KCNE3) to underlie one form of periodic 
paralysis (Abbott et al. 2001). 
In conclusion, several disease genes 
for arrhythmic disorders still await 
identification. The characterization of these 
genes and their mutations will provide 
a molecular diagnosis for an increasing 
number of individuals. Even more 
importantly, identification of the novel 
disease genes will enable the investigation 
and clarification of molecular pathogenic 
mechanisms underlying the disease 
phenotypes, and thus provide a basis for 
new therapeutic interventions. 
60
CONCLUSIONS
CONCLUSIONS
Inherited arrhythmic syndromes involving 
no structural abnormalities of the heart 
muscle are rare but clinically important 
entities. This study investigated the genetic 
background of two of these diseases, 
catecholaminergic polymorphic ventricular 
tachycardia (CPVT) and long QT syndrome 
(LQTS). At the commencement of this 
study, the genetic locus of CPVT had been 
mapped to chromosome 1q42-43, and 
several genes underlying LQTS had been 
described. The main results and conclusions 
of the present study are as follows:
• The location of the gene causing CPVT 
was narrowed to a region of 1.5 cM. 
Several functionally relevant positional 
candidate genes were screened for 
mutations. Subsequently, mutations 
were identified in the gene coding for 
ryanodine receptor type 2 (RYR2), a 
calcium-release channel located in the 
sarcoplasmic reticulum. This study 
revealed the genetic background of six 
Finnish CPVT families.
• In functional studies, the mutant 
RYR2 channels displayed increased 
open probability. This is in line with 
the hypothesis that the channels 
inappropriately leak calcium into the 
cytoplasm. In addition, the mutant 
channels displayed insensitivity to the 
physiological inhibitor magnesium. 
Treatment with the experimental 
drug JTV519 normalized the channel 
function. These data may have 
relevance to patient treatment in the 
future.
• While this study was in progress, the 
gene underlying recessively inherited 
CPVT was identified as calsequestrin 
2 (CASQ2). This gene was screened 
for mutations in Finnish CPVT 
probands, and two novel amino acid 
polymorphisms were detected but no 
pathogenic mutations. Thus far, CASQ2 
does not appear to be a major cause of 
Finnish CPVT.
• A known LQTS-causing gene, 
HERG, was screened for mutations 
in 40 Finnish LQTS probands. 
Nine mutations, including two 
small deletions and seven missense 
mutations, were detected in this gene 
coding for a delayed rectifier potassium 
channel. One of the point mutations 
(L552S) represented a Finnish founder 
mutation and was therefore designated 
HERG-Fin. This mutation accounts 
for approximately 10% of molecularly 
defined Finnish LQTS cases.
• The first common amino acid 
polymorphism in the HERG gene 
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was also identified. For a study of 
the phenotypic effects of K897T 
polymorphism, 170 individuals 
carrying a Finnish founder mutation 
KCNQ1-Fin underwent screening 
for this polymorphism. A genotype-
phenotype relationship was suggested, 
but additional studies are required for 
confirmation of this result.
• The functional properties of the HERG-
Fin mutation were studied with a patch-
clamp technique. The mutant channel 
showed an increased deactivation rate 
that may result in decreased channel 
activity at the end of the repolarization 
phase.
• The results of this study are useful in 
the molecular diagnosis in each of the 
affected LQTS families. As a result of 
this study, all Finnish LQTS probands 
are routinely screened for the presence 
of the HERG-Fin mutation. Molecular 
diagnosis is of major importance 
as it also identifies asymptomatic 
individuals who may be at risk for 
drug-induced arrhythmias. 
• In CPVT, the first symptom may be 
lethal, and beta-adrenergic blocking 
therapy has been effective in preventing 
malignant arrhythmias. DNA-based 
diagnosis in the CPVT families 
therefore provides an important asset 
in identifying affected individuals 
presymptomatically. No sudden cardiac 
deaths have occurred in our Finnish 
CPVT families since the time that the 
patients were recruited to this study.
• Identification of the mutations 
underlying CPVT and LQTS has 
enabled investigation of the functional 
defects that lead to arrhythmia 
induction.
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